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ABSTRACT 
Background: Despite technological and programmatic advances in the prevention of vertical 
transmission of HIV and early infant diagnosis (EID), paediatric HIV continues to have a 
significant impact on infant and child survival in low- and middle-income countries. Many 
EID programmes follow the WHO recommendation of initial infant HIV testing with a nucleic 
acid assay at 4-6 weeks old. In general this strategy has been poorly implemented with 
substantial attrition after birth such that, according to UNAIDS, only 51% of HIV-exposed 
infants received a virological test in the first two months of life in 2015. In addition, there is 
concern about the sensitivity of the nucleic acid assays at six weeks in the context of 
exposure to prolonged multidrug antiretroviral therapy as infant post-exposure prophylaxis, 
and in breast milk. HIV-PCR testing at birth has been promoted as a means of maximizing 
the number of infants who receive an HIV test as well as identifying in utero-infected infants 
in whom HIV infection may follow an aggressive course. 
Evidence from pilot studies and modelling data was sufficiently compelling for the WHO to 
include a conditional recommendation for the addition of a birth HIV-PCR (either routine or 
targeted at high risk groups) to its EID algorithms in 2015. The Western Cape introduced 
targeted birth HIV testing for high risk infants in August 2014 and expanded this in line with 
the South African National Prevention of Mother-to-Child Transmission Guidelines, to 
include all HIV-exposed infants in December 2015.  
Methods: Between 2013 and 2016 we conducted an implementation science project to 
iteratively assess the implementation and effectiveness of the vertical transmission 
prevention of HIV in a chain of referral facilities in Cape Town (i.e. from primary to tertiary 
care). The e-register provided a single longitudinal record for each woman (linked to her 
infant after birth) and enabled assessment of HIV testing and treatment from first antenatal 
visit through delivery to infant HIV testing.  
Using a cohort of HIV-exposed live infants from this database, a protocol was designed 
(Section A: Protocol) to assess the implementation and outcome of effectively three 
different EID policy periods in the facility chain. i.e. an initial period of birth HIV-PCR at the 
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clinician’s discretion if evidence of HIV infection; a period of targeted birth testing of high 
risk infants and lastly, of routine birth HIV-PCR for all HIV-exposed infants. 
A critical review of the literature appraised published assessments of birth HIV testing 
programmes in low- and middle-income countries (Section B: Literature Review) with the 
aim of assessing in utero transmission rates, follow-up testing and transmission rates and 
the resources required for implementation. Studies that modelled the impact of birth HIV 
testing were specifically reviewed.  
The manuscript (Section C: Manuscript) presented an analysis of the HIV-infected/exposed 
mother/infant dyads from the e-register of the Closing the Gaps study. Using this database 
adherence to guidelines in each period was assessed as well as the outcome of HIV-PCR at 
four delivery sites and the impact of the policies on return for follow-up EID. 
Results: South Africa is the first country in sub-Saharan Africa to implement birth HIV testing 
and most of the studies in support of this strategy were generated here. There was limited 
literature which highlighted the need for further investigation into the implementation and 
effectiveness of such programmes. No prospective data addressed targeted birth testing 
and those reporting on more routine birth HIV-PCR demonstrated success in timeous 
diagnosis and treatment although significant additional project resources were required. 
The retrospective laboratory data indicated that receipt of a birth HIV-PCR reduced the 
likelihood for follow-up at later testing time-points. This is important as the modelling 
studies suggested that the clinical and financial benefits of adding birth testing to existing 
algorithms would be lost if follow-up was poor. 
In the cohort of 2012 HIV-exposed infants in the study presented in the manuscript, the 
proportion who received birth testing increased with the progression of the EID policies but 
guideline implementation was poor, especially in primary care, with only 60% of infants 
being tested as recommended. The proportion of infants with positive HIV-PCR decreased as 
the pool of HIV-exposed infants undergoing testing expanded, being highest during the 
periods of targeted birth testing. In concurrence with the South African literature, receipt of 
a birth HIV-PCR decreased the likelihood of follow-up testing at 6-10 weeks. Among infants 
tested at 6-10 weeks old, the proportion who were positive for the first time at this time-
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point increased with the introduction of routine birth testing for all HIV-exposed infants, 
emphasizing the importance of the follow-up EID time-points. 
Conclusion: Virological testing at birth effectively increased the number of HIV-exposed 
infants who received an HIV test and was effective in identifying in utero infection in high 
risk infants (who could start treatment early with the attendant benefits.) The Western Cape 
EID policies were incompletely implemented in the study facilities over this time with many 
infants not being tested as indicated. Birth HIV-PCR decreased follow-up testing, an 
unintended consequence of serious concern. Adherence to the provincial and national 
guidelines needs to be re-enforced at delivery sites and at the primary care facilities where 
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PART A. RESEARCH PROTOCOL 
SYNOPSIS 
Title:  A longitudinal analysis of neonatal and infant diagnostic HIV PCR uptake and 
associations during three sequential policy periods in Mitchell’s Plain, Cape Town 
Background and Rationale: WHO guidelines recommend nucleic acid testing (HIV DNA-PCR 
or equivalent) of HIV-exposed infants between 4-6 weeks of age.  At this time-point most in 
utero and intra-partum HIV infections can be detected; in addition it is programmatically 
convenient as it coincides with a routine immunization visit. There is a subsequent visit at 10 
weeks old at which the results can be returned. However, there is significant attrition before 
4-6 weeks and the majority of HIV-exposed infants are not tested by two months old; and, 
operationally antiretroviral therapy (ART) initiation may be delayed in HIV-infected infants 
with consequences for morbidity and mortality. In 2015 the WHO added a conditional 
recommendation for diagnostic HIV PCR testing of HIV-exposed infants at birth to identify in 
utero infected neonates in addition to testing at a later time-point. Prior to the WHO 
recommendation, in 2014 the Western Cape Province added birth HIV PCR testing for 
neonates at high risk of vertical infection to the early infant diagnosis (EID) algorithm; and in 
2015 routine birth testing was introduced for all HIV-exposed infants. The implementation 
and impact of these guideline changes are unknown. 
Purpose and Objectives: The purpose of this study is to examine the uptake of HIV PCR 
testing under three different EID policies (i.e. six weeks only; birth for high risk infants and 
six weeks; and birth for all exposed infants and 10 weeks) in the Western Cape, and the 
diagnostic yield at each time-point. Findings will be placed in the context of the evolving 
local prevention of vertical transmission of HIV recommendations and international clinical 
and programmatic guidelines. 
Methods: The proposed project is a sub-analysis of data collected from the larger Closing 
the Gaps study, an implementation science project which developed an electronic system 
allowing iterative assessment of the vertical transmission prevention of HIV programme at a 
facility and individual level. We will include live infants born to HIV-infected women who 
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received antenatal care and/or delivered at Mitchell’s Plain Midwife Obstetric Unit and its 
referral centres in Cape Town between February 2014 and June 2016.   
Descriptive statistics will be used to describe HIV PCR testing uptake and how this changed 
as the EID programme evolved.  Logistic regression will be used to determine predictors of 
testing uptake in the context of the different guidelines.  
Risks and Benefits: The major risk of this sub-study mirrors that of the parent project: 
breach of confidentiality as study staff (EK) will have access to individually identifiable 
maternal and infant HIV-related data.  
Risks, Potential Benefits and Protection Against Risks: Inclusion of identifiers in the database 
is necessary initially so that women and their infants can be linked and the data cleaned 
(which may require return to the original sources). Identifiers will be removed from all data 
as soon as linkage and cleaning are complete. Only staff directly involved (EK) will have 
access to any individually identifiable data. EK has undergone the NIH Human Subjects 
Protection training, has completed Good Clinical Practice training in the past and, as a 
registered medical practitioner with the HPCSA is bound by professional medical standards. 
All electronic data will be password-protected and stored on a secure server housed in the 
CIDER offices at the UCT, with user-level access control. 
The risk of breach of confidentiality is small and the study is considered low-risk. 
There are no direct benefits to the participants. Indirectly, the analysis will allow 
measurement of the uptake of HIV PCR testing and HIV diagnosis rates during three 
different EID strategies as they were implemented in the Mitchell’s Plain over the study 
period. Such evaluation is important locally and internationally; South Africa is one of the 
few low or middle income countries where birth HIV testing has been introduced and such 
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PROTOCOL 
A longitudinal analysis of neonatal and infant diagnostic HIV PCR uptake and associations 
during three sequential policy periods in Mitchell’s Plain, Cape Town 
1. Background 
Despite advances in prevention of vertical transmission of HIV strategies and treatment, 
paediatric HIV infection remains a global challenge. Without treatment, HIV infection is 
rapidly progressive in infants and young children with 50% mortality within the first two 
years of life (1). In South Africa, mortality of vertically infected untreated infants peaks at 2-
3 months of age (2). Evidence from observational studies and randomized controlled trials 
(most notably the Children with HIV Early Antiretroviral Therapy [CHER] trial (3)) indicates 
that early treatment of HIV infected infants with antiretroviral therapy (ART) reduces 
mortality and abrogates early and long-term complications (4, 5). In the CHER study ART 
initiated before seven weeks of age was associated a 76% decreased mortality and a 75% 
drop in HIV disease progression (3).  More recent data suggest that early treatment (within 
hours to days of birth) can limit viral replication and reduce immune suppression and 
physiological damage (6).  
Early ART initiation, with its attendant benefits, depends on early diagnosis of HIV infection. 
Diagnostic technological advances have now pushed back diagnostic possibility to within 
hours of birth. 
Since 2007 the World Health Organization (WHO) recommendation for early infant diagnosis 
(EID) has been an initial nucleic acid test (HIV PCR) at six weeks old (7, 8). Early studies 
indicated that testing at this time point would detect the majority of in utero and intra-
partum infections and operationally it coincides with the routine six week extended 
programme on immunization (EPI) vaccination visit recommended by the WHO (9, 10). Since 
the above studies were conducted, prevention of vertical transmission of HIV (VTP) 
programmes have expanded in sophistication and scope with prolonged and more effective 
drug treatment and more sensitive and efficient diagnostic assays (11).  In South Africa the 
majority of HIV-infected pregnant women who attend antenatal care are initiated on ART 
(93% in 2015/2016(12)) and intra-partum transmission (which accounted for upward of 50% 
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of infant HIV infections in untreated women (13)) has been reduced. As a result a larger 
proportion of infant infections are due to in utero (i.e. before starting ART) and post-partum 
transmission. 
These advances, together with the clinical benefits of very early ART initiation, have called 
into question the appropriateness of the six week time point for initial diagnostic HIV 
testing. Prolonged infant post-exposure prophylaxis and maternal ART now routine in many 
VTP programmes in low and middle income countries (LMIC) and the sensitivity and 
specificity of the diagnostic HIV PCR at six weeks in this context is unclear.  
In sub-Saharan Africa, there is significant attrition from VTP care with the majority of HIV 
exposed infants failing to receive the six week HIV PCR (14). This, coupled with laboratory 
delays and difficulties communicating results to sites, resulted in only an estimated 50% of 
HIV-infected infants initiating ART in 2016 (15). Even when programme timelines are 
observed, infants testing HIV positive at six weeks old may only initiate treatment at 14 
weeks, beyond the recommended seven weeks of CHER and the 2-3 month peak in HIV-
related mortality (2, 3, 16). Evidence from Johannesburg suggested that 76% of infant HIV 
infections diagnosed at six weeks could be detected at birth, potentially allowing for more 
rapid ART initiation. In settings with high rates of institutional deliveries, such as South 
Africa, birth testing would achieve higher coverage than the six week test (11) and, models 
suggest, save the same number of life years (17).  Furthermore, the potential clinical 
benefits of early treatment (hours to days) in preserving immune function and restricting 
viral reservoirs support the move to a more timeous diagnosis (6). 
Given these issues, the WHO included a conditional recommendation in the 2015 VTP 
guidelines for an HIV PCR around birth (0-2 days) in addition to testing at 4-6 weeks (8). The 
rationale being that testing soon after birth would identify infants infected in utero in whom 
HIV disease is severe and rapidly progressive allowing timeous initiation of ART. In settings 
were the majority of births occur in health facilities, exposed neonates could be tested 
before discharge and resources focused on drawing positive infants into care. Concerns 
about the sensitivity of the PCR assays in the presence of prolonged infant prophylaxis (for 
example, daily nevirapine [NVP] for at least six weeks) would not apply (16). 
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Early Infant Diagnosis in the Western Cape (Figure 1)  
In line with the South African National Guidelines, the 2013 Western Cape Prevention of 
Mother-to-Child Transmission of HIV (PMTCT) Clinical Guidelines Update recommended 
routine HIV PCR of all HIV exposed infants at six weeks old (18). Provision was made for a 
diagnostic PCR at birth at the attending clinician’s discretion (e.g. in situations of suspected 
nevirapine [NVP] resistance or clinical symptoms). In July 2014 an additional test at birth 
was added for those infants who met high risk criteria for vertical infection (19)(Table 1.)
The South African National Consolidated Guidelines for the Prevention of Mother-to-Child 
Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and 
Adults introduced routine HIV diagnostic testing for all HIV-exposed infants at birth in 2015 
with repeat testing at 10 weeks to identify peri-partum and early postnatal infections (20). 
This was implemented in the Western Cape in November 2015 (21). 
Thus, over the projected course of this project, the Western Cape EID recommendations 
were updated twice allowing us to assess uptake and results of HIV PCR testing under three 
different EID strategies (Figure 1). 
Period 1: Routine PCR at six weeks old; birth PCR at clinician’s discretion. 
Period 2: Birth PCR for infants meeting high risk criteria for vertical transmission of HIV 
(Table 1) with routine diagnostic testing at six weeks old. 
Period 3: Routine birth PCR for all HIV-exposed infants with follow-up PCR at 10 weeks old. 
Figure A.1. Evolving Western Cape Prevention of Mother-to-Child Transmission of HIV guidelines 
giving three policy periods between 2013 and 2016. 
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MATERNAL FACTORS INFANT FACTORS 
Viral load >1000 copies/ml after 28 weeks 
gestation 
Born before 37 weeks gestational age 
ART < 12 weeks of before delivery Birthweight < 2500g regardless of gestation 
 Abandoned babies and orphans 
Newly diagnosed with HIV > 28 weeks gestation 
including during labour/immediately postpartum 
Symptomatic  
Likely NNRTI resistance (on 2nd/3rd line ART 
during pregnancy 
 
Diagnosed with TB or syphilis during pregnancy  
Clinical signs of chorioamnionitis  
Table A.1. Criteria for identifying HIV exposed infants at high risk of vertical infection (birth PCR 
indicated in terms of the 2014 Western Cape Guidelines (22)) ART – antiretroviral therapy; NNRTI – 
non-nucleotide reverse transcriptase inhibitor; TB – tuberculosis disease 
 
2. Justification 
There has been rapid, if patchy, uptake of birth HIV PCR testing in South Africa since 2013 
but limited assessment of its impact (12). Review of routine programme implementation 
was identified as a research priority by the National Institute of Allergy and Infectious 
Diseases workshop on “HIV Birth Testing and Linkage to Care for HIV Infected Infants” in 
2016, the aim of the which was to specifically evaluate birth testing (23). The project offers 
the opportunity to measure and compare the uptake and impact of birth HIV PCR testing at 
different levels of care (primary, secondary and tertiary) and under three different EID 
policies. 
In addition, it is critical that infants with a negative birth HIV test result return for repeat 
testing (at 10 weeks old according to current local recommendations) to detect intra-
partum and early post-natal infections, and that ART is initiated rapidly. There are concerns 
that receipt of a negative birth HIV PCR result will reduce return for follow-up testing. 
This study will allow us to assess adherence to provincial guidelines, the usefulness of HIV 
PCR testing at birth at different delivery sites and the impact on presentation for follow-up 
HIV PCR testing in a single referral system under the three different EID strategies described 
above. 
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3. Hypotheses 
Hypothesis 1:  Birth HIV PCR testing has improved the overall proportion of HIV-exposed 
infants tested as part of EID. 
Hypothesis 2:  The VTP programme in the Western Cape is effective and incidents of vertical 
transmission are typified by certain characteristics (risk factors). 
Hypothesis 3:  Receipt of a negative birth HIV PCR result decreases up-take of follow-up HIV 
PCR testing at 10 weeks and beyond.  
4. Aim 
The overall aim is to describe the uptake of HIV PCR testing (EID) by HIV-infected women 
who attended a single primary care antenatal site under three sequential EID policy periods 
and to determine associations between timing of HIV PCR testing and clinical and 
demographic characteristics in each of these. 
5. Objectives: 
1. To described the implementation of the Western Cape Provincial EID guidelines including 
the uptake of infant HIV PCR testing (birth and subsequently) by HIV-infected women during 
three sequential EID policy periods. 
2. To determine the clinical and demographic associations that impact on the EID uptake at 
different time-points (i.e. birth and 6-10 weeks). 
3. To determine the proportion of positive HIV PCR results and describe clinical and 
demographic characteristics of HIV-infected infants. 
6. Methods 
This project will form a sub-analysis of the larger, Closing the Gaps (CTG) study (Appendix 1).  
CTG was an NIH-funded implementation science project in the form of a prospective cohort 
of pregnant women and their infants comparing the VTP coverage and effectiveness before 
and after the implementation of an active VTP surveillance system – an electronic or e-
register.  Using the existing medical records systems, CTG utilized routinely collected clinical 
data from existing Provincial data sources, namely the paper-based obstetric registers in use 
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at Mitchell’s Plain Midwife Obstetric Unit (MPMOU) and the referral hospitals. Data 
elements from the antenatal HIV testing registers, the labour ward HIV PMTCT registers, and 
delivery (birth) registers were consolidated into the e-register. HIV-associated laboratory 
data and ART prescription data were included. 
6.1 Study design 
Prospective cohort study 
6.2 Population and sampling 
This study will utilize data from the live infants born to HIV-infected women in the CTG 
cohort.  The CTG database comprised all pregnant women who presented for antenatal care 
at the MPMOU in Cape Town and who delivered at MPMOU or any of its referral centres 
(Mitchell’s Plain District, Mowbray Maternity and Groote Schuur Hospitals) between 
February 2014 and June 2016. Pregnant women (regardless of HIV status) were enrolled 
prospectively as they presented at the facility for their first antenatal visit or in labour if they 
had not received any antenatal care. There were no exclusion criteria. 
Clinical and socio-demographic characteristics  
Mitchell’s Plain Community Health Centre, of which MPMOU is a part, has catchment area 
of approximately 1.2 million people covering the geographic areas of Mitchell’s Plain (an 
urban lower to middle income historically “Coloured” township with formal housing)  and 
the neighboring suburbs of Phillipi and Crossroads housing poorer, predominantly black 
African communities.  In these areas there is a mix of formal and informal housing. 
Unemployment was 24.2% in 2015 (24).  
Women received antenatal care at MPMOU or nearby basic antenatal care (BANC) clinics. 
Uncomplicated vaginal births were managed by midwives at the MOU. Approximately half 
of all women who attend the facility antenatally were referred to hospital either during 
pregnancy or peripartum if deemed high risk or requiring advanced care. MPMOU refers to 
Mitchell’s Plain District Hospital (level 1 with operating theatres), Mowbray Maternity 
Hospital (level 2 with neonatal ICU facilities), and Groote Schuur Hospital (level 3 with adult 
and neonatal ICU facilities). 
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6.3 Sample size  
Approximately 7000 women attend antenatal care (book) at MPMOU per year about half of 
whom deliver at the facility (the remainder being referred to hospital).  HIV prevalence at 
delivery during the study period was 14% and we would expect approximately 2000 HIV-
exposed infants over two years. 
6.4 Research procedures and data collection methods 
This analysis will use data collected as part of the CTG study. CTG enrolled women between 
February 2014 and June 2016. Delivery information was collected through the end of 2016. 
Women identified as HIV-infected will be extracted from the larger database of the entire 
CTG cohort and pregnancy losses excluded, giving a cohort of HIV-exposed live-born infants. 
The maternal data will be linked via infant folder number with the corresponding infant 
profiles to allow analysis of maternal and delivery information and infant anthropometry 
and HIV test results. The Western Cape Province has introduced a system of unique patient 
identifiers: all clients of the provincial health services use the same unique folder number at 
every facility. Blood and other laboratory tests are also requested with this number. Thus all 
HIV-relevant laboratory investigations (e.g. maternal viral load and infant HIV PCR; see 
below) can be confirmed, and mothers and their infants linked. 
All data will be de-identified before analysis.  
Exposures 
The antenatal HIV prevalence in the Western Cape at the time of data collection was 18.7% 
(25). The Western Cape Provincial Government PMTCT clinical guidelines underwent two 
updates during the study period (Figure 1). WHO Option B+ was introduced in the Province 
in 2013 and this was the overall strategy throughout the study. WHO Option B+ 
recommends initiating lifelong ART (i.e. treatment with three antiretroviral agents from two 
different classes) in all HIV-infected pregnant women regardless of clinical or immunological 
stage; it replaced less aggressive strategies which prescribed single or dual VTP prophylaxis 
for women with higher CD4 cell counts. Maternal first-line ART consisted of tenofovir (TDF), 
emtricitabine (FTC) and efavirenz (EFV). HIV-exposed infants received six weeks of daily NVP 
if the mother had received more than eight weeks of ART before delivery or had elected to 
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exclusively formula feed. Breastfed infants whose mother’s had received less than eight 
weeks ART antenatally were given daily NVP for 12 weeks. For infants at high risk of 
transmission zidovudine (AZT) was added. In 2015 these were amended: those neonates at 
low risk of transmission at birth received six weeks of NVP regardless of feeding choice. For 
high risk infants NVP was extended to 12 weeks and AZT added for the first six weeks(26). 
HIV PCR testing schedules are described in Figure 1 above. The PMTCT and EID algorithms 
for each period are detailed in Appendix 2. 
Well baby clinics and infant HIV PCR testing usually occurred at sites separate from the 
maternity facilities and in some cases were managed by a different arm of local 
government.  At these sites, clinic staff ascertained HIV-exposure status (and hence the 
need for an HIV PCR) either from the caregiver or from the client-held Road-to-Health book 
given to all infants born in South Africa which serves as a record of birth, immunizations, HIV 
exposure and VTP, and growth. 
Laboratory measurements 
Relevant laboratory results from the NHLS (i.e. maternal CD4 count and viral load 
measurements, and infant HIV PCR results) were abstracted from the electronic NHLS 
platforms and entered into the e-register. The NHLS provides a quality controlled and 
validated laboratory service for all government health facilities. In order to ensure that all 
available results are collected, an output of relevant results for CTG participants will be 
requested from the Provincial Health Data Centre (PHDC) which acts as a repository for all 
electronic medical systems including the NHLS.  
Linking maternal and infant data 
At all primary health care facilities in the Western Cape Province, including MPMOU, 
appointments and key delivery data are entered on the Primary Health Care Information 
System (PHCIS). After delivery and before the mother-infant pair is discharged, selected 
delivery data are entered in the Maternity Module of PHCIS and an infant folder number is 
automatically generated. This links the mother-infant pair and is recorded in the maternity 
record and infant Road-to-Health book. The equivalent hospital system, Clinicom, generates 
a linked infant folder number in a similar process.  These infant numbers were entered into 
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the maternal profile in the e-register of the CTG cohort allowing linkage of maternal and 
infant data. 
PHCIS data entry at MPMOU was done by the midwives and compliance was poor at the 
start of the project, resulting in missing infant numbers and incomplete linkage.  This 
improved within four months of the study and the majority of live-born neonates were 
appropriately identified. The sample will be limited to those mother-infant pairs whom we 
were able to link. 
Maternal entries containing relevant results and delivery information will be linked with 
infant entries recording birth anthropometry and HIV-related blood results. 
Endpoints/variables 
Using the cohort of HIV-exposed live-born infants with an unique identifier, evidence of all 
HIV PCR tests per infant in defined time periods and the results of these will comprise the 
main outcome variables. Participants will be categorized as follows: no HIV PCR before 11 
weeks old, birth HIV PCR only, birth HIV PCR and follow-up PCR (6-10weeks), HIV PCR at 6-
10 weeks only. 
Associations of testing at the different time-points with maternal and infant characteristics 
(including the high risk criteria) will be assessed (Table 2). 
6.5 Data management 
Closing the Gaps was an implementation science project and efforts were made to use 
existing facility systems. Routinely collected data was entered directly from the clinical 
records into eKapa, the networked electronic medical records system in place at MPMOU. 
At the time of the study, eKapa was in routine use for the capture of HIV-related patient 
information in HIV-infected patients but did not include any obstetric parameters.  We 
augmented the routine system to include HIV negative women as well as obstetric data on 
all women which was entered into a Study Module.  Individual records were created for 
infants which were subsequently linked to the corresponding maternal records via the 
infant folder numbers as described. Exports of data on enrolled subjects were requested for 
cleaning and then analysis.  
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Using the export of raw data from the CTG cohort I will restrict the sample to pregnant 
women identified as HIV-infected. From these women I will extract those who had the live 
births (excluding pregnancy loss [stillbirth, miscarriage, termination of pregnancy, ectopic 
pregnancy and molar pregnancy], false pregnancies and those for whom no outcome can be 
found). I will merge these records with the corresponding infant records using the infant 
identifier resulting in a database of HIV-exposed live born infants, and including the 
variables outlined below. If no infant number can be established, the mother-infant pair will 
be excluded. 
Once these linkages are complete, I will allocate a unique study identifier to each participant 
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Variable Description Detail 
PMTCT policy period Categorical  (Period 1,2 or 3) 
High risk factor* Binary (present/absent)  
Delivery at hospital Binary (yes/no) 
Versus primary care facility (i.e. 
MPMOU) 
Mode of delivery Categorical Vaginal/Assisted/Caesarian  
Maternal factors 
Age (years) Numerical - continuous   
Primigravida  Binary (yes/no) 
Versus second or subsequent 
pregnancy 
Viral load >1000 copies/ml 
after 28 weeks gestation 
Binary (yes/no/not available)  
ART < 12 weeks of before 
delivery 
Binary (yes/no/not available)  
during pregnancy 
Binary (yes/no/not available)  
Newly diagnosed with HIV > 28 
weeks gestation including 
during labour/immediately 
postpartum 
Binary (yes/no)  
No antenatal care Binary (yes/no/not available)  
Neonatal factors 
Premature birth : <37 weeks 
gestation† 
Binary (yes/no)  
LBW <2500g regardless of 
gestation 
Binary (yes/no)  
Table A.2. Variable list: baseline characteristics including high risk factors for vertical transmission 
of HIV 
*High risk factors: Viral load >1000 copies/ml after 28 weeks gestation; ART < 12 weeks of before 
delivery; Newly diagnosed with HIV > 28 weeks gestation including during labour/immediately 
postpartum; No antenatal care; Premature birth; LBW 
†Gestational age as recorded in the labour ward delivery registers at the site. This is usually based on 
antenatal assessment as Ballard Scores are not routinely performed. 
PMTCT – Prevention of Mother-to-Child Transmission; MPMOU – Mitchell’s Plain Midwife Obstetric 
unit; ART – Antiretroviral Therapy; LBW – Low Birth Weight 
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6.6 Analysis 
Data will be analyzed using STATA version 15.0 (Stata Corporation, College Station, Texas, 
USA).  
Continuous variables will be summarized using means and confidence intervals (CI) or 
medians and interquartile ranges (IQR) for normally and non-normally distributed variables 
respectively.  Categorical variables will be described using proportions and frequency tables 
will be used to compare proportions. 
Significance will be tested using a two-sample t-test or Wilcoxon rank-sum test depending 
on the distribution for numerical data and 
data.  
Logistic regression will be used to identify the predictors of PCR timing. Multivariate models 
will be fitted including known or suspected risk factors for the primary outcomes. 
A significance level of 0.05 will be used for all statistical tests. 
7. Ethical considerations 
The Closing the Gaps study was approved by the Human Research Ethics Committee of the 
University of Cape Town (HREC: 145/2013; Appendix 3) and the Provincial Government of 
the Western Cape Department of Health Research (RP063/2013; Appendix 3). This protocol 
comprises the application for the sub-analyses described above. 
The CTG electronic register used patient folder number (maternal and infant), name, birth 
dates and delivery dates as linkage fields when consolidating the registers and laboratory 
results and when linking mother and infant.  
7.1 Informed consent 
There was no recruitment for the electronic register and a waiver of informed consent was 
granted for this part of the project since only data that was already part of routine care by 
the health services were collected. Data were entered on the existing provincial medical 
records platform by a single trained data clerk who was bound by professional and ethical 
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considerations when she was granted access to the system. She completed the NIH 
Protection of Human Subjects on-line training. 
7.2 Description of risks and benefits 
The major risk of this study is breach of confidentiality as I will have access to individually 
identifiable maternal and infant health information including HIV data. The study is 
considered to be low risk with the potential for loss of confidentiality during the process of 
data cleaning and linkage.  
 
7.3 Protection against risks  
Since every effort will be taken to ensure confidentiality, the small risk of it being breached 
can be considered to be acceptable. To minimize the risk of breaching confidentiality, all 
electronic data will be stored in a password-protected database on a secure server housed 
in the CIDER offices. As soon as linkage and data cleaning are complete all identifiers will be 
removed, prior to analysis. A unique study identifier will be allocated to each participant and 
data analysis will be conducted on an anonymized dataset. 
Any data transfer will be done securely with password protection via the UCT data transfer 
web-platforms, the passwords being sent separately and by a different route (e.g. text 
message to mobile phone) to the databases.  
 
7.4 Potential benefits 
There is no direct benefit to participants as this will be a retrospective analysis of routinely 
collected clinical data. 
Indirect benefit will stem from the analysis of the database which may identify gaps or 
challenges in the implementation of the Provincial VTP guidelines. In addition, variables 
associated with a high risk of vertical transmission or failure to implement guidelines may be 
ascertained, allowing for the antenatal identification of vulnerable women and infants who 
may require additional services and support. Ideally, such systems could be incorporated 
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7.5 Reporting and implementation 
The results of this sub-study will be submitted to a peer-review publication and presented at 
appropriate conferences. A report will be submitted to the HAST directorate at the KMP SS 
and the facility and operational managers at the MPMOU, MPDH, MMH and GSH for 




Merge, clean and check datasets 9 months 
Analysis  2 months 
Preparation draft manuscript 2 months 





This analysis and write-up will form part of the requirements for my MPH and no budget is 
required. 
9. Appendices  
Appendix 1:  Closing the Gaps in PMTCT Programme Coverage, Early Infant Diagnosis and 
Treatment (CTG) 
Appendix 2: Western Cape Vertical Transmission Prevention of HIV and Early Infant 
Diagnosis Algorithms 
a) PMTCT Clinical Guidelines Update May 2013 
b) PMTCT Clinical Guidelines Update June 2014 
c) Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother-to-Child 
Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2015 (Amended version) 
Appendix 3:  UCT Human Research Ethics Committee approval (145/2013); PGWC Health 
Research approval (RP063/2013) 
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PART B. LITERATURE REVIEW 
1. Background 
Paediatric HIV infection remains an important health challenge globally (1, 2). Observational 
studies and randomised controlled trials confirm that early initiation of antiretroviral 
therapy (ART) in HIV-infected infants substantially reduces mortality and acute and chronic 
morbidity (3-5). Furthermore, clinical evidence suggests that initiation of ART within hours 
to days of birth can preserve immune function and limit viral dissemination with positive 
consequences for growth and development (6, 7). Timeous treatment requires early 
diagnosis. Technological developments in nucleic acid testing (DNA/RNA PCR or a 
combination of the two, henceforth denoted HIV-PCR) have increased the sensitivity and 
specificity of birth HIV diagnostic assays (8, 9).  Together with programmatic advances this 
has allowed the use of technology at scale to make such testing feasible even in some 
resource-limited settings. 
With the evolution in the scope and sophistication of vertical transmission prevention of HIV 
(VTP) strategies, programmatic and therapeutic, and the overwhelming evidence of the 
benefits of early ART in infants, the appropriateness of the World Health Organization 
(WHO) recommendation of an initial diagnostic HIV-PCR at six weeks old has been 
questioned in some settings (9). The 2016 WHO Consolidated Guidelines on the use of 
Antiretroviral Drugs for Treating and Preventing HIV Infection included a conditional 
recommendation for HIV-PCR testing at birth in addition to existing testing algorithms (1). 
The South African National Consolidated Guidelines for the Prevention of Mother-to-Child 
Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and 
Adults introduced routine diagnostic testing for all HIV-exposed infants at birth in 2015 with 
repeat testing at 10 weeks old (10). The rationale behind this recommendation is that 
testing at birth would identify all neonates infected in utero who could then be fast-tracked 
to treatment. Repeat testing at 10 weeks would detect peri-natal and early post-partum 
infections. Ten weeks coincides with the second routine visit of the WHO’s Expanded 
Programme on Immunization schedule (11). 
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2. Objectives 
Programmatic data on the impact of birth HIV-PCR testing of HIV-exposed infants in sub-
Saharan Africa is lacking (12, 13). This review aims to appraise published assessments of 
birth HIV-PCR testing programmes in low and middle income countries (LMIC), to summarise 
existing knowledge and identify research gaps.  
There is considerable debate as to the appropriateness and cost effectiveness of birth HIV-
PCR testing versus testing at other time-points in resource constrained settings, owing to 
the high cost nucleic acid tests. Since birth testing identifies in utero HIV infections only, 
subsequent early tests would be necessary to detect peri-natal and early post-partum 
infections (1, 14-16). While acknowledging these controversies, this review is confined to 
assessment of birth testing programmes. Some discussion of optimal time points and 
costing will be included in the analysis of the modelling literature. 
The specific objectives of the review are to report on: 
Proportion HIV infected infants identified at birth and overall in utero HIV 
transmission rate 
Performance of the diagnostic assays 
Age of follow-up HIV-PCR 
Linkage to care/time to ART in HIV-infected infants 
Resources required for implementation of birth HIV-PCR 
Studies modelling the impact of birth HIV-PCR will be reviewed specifically 
3. Concepts and Definitions 
The definition of early infant diagnosis (EID) has evolved with technological and operational 
advances allowing us to confirm diagnosis within hours of birth, but also requiring that we 
extend monitoring prospectively through the entire exposure period to the end of breast-
feeding (3). Mother-to-child transmission of HIV (MTCT) can occur during pregnancy, labour 
and delivery, and post-partum via breastmilk. Based on data from VTP randomized 
controlled trials, Kourtis et al. proposed estimates for the timing of MTCT (without any 
antiretroviral intervention). In a non-breastfeeding population, the majority of transmission 
occurs during late pregnancy and delivery (peri-natal infection;~80%) with approximately 
20% occurring in utero; that is, during pregnancy. In populations with prolonged breast-
feeding (up to 24 months), an estimated 40% of MTCT occurred during the post-partum 
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period, 50% peri-natal and 10% in utero (17). Initial drug-based VTP interventions covered 
the high risk peri-natal period, changing these proportions. Under the WHO option B+ 
PMTCT guidelines in which HIV-infected pregnant women are initiated on ART for life at 
diagnosis regardless of immunological or clinical stage of disease, many more pregnancies 
are protected by ART for longer periods. Evidence suggests that under these circumstances 
in utero, and particularly post-partum transmissions will comprise the majority of infections 
(9). 
Definitions  
In utero transmission of HIV: HIV-PCR positive in blood samples within 3 days of birth (18).  
Intrapartum transmission: HIV-PCR negative in blood samples within 3 days of birth but 
subsequently positive (non-breast-feeding population; in the presence of breast-feeding is it 
difficult to distinguish from early post-partum transmission) (18). 
Post-partum transmission: HIV-PCR negative in blood samples at birth and 6-10 weeks old 
but subsequently positive in the presence of breast-feeding (19).  
Diagnostic Assays in Infants and Young Children 
Maternal HIV-specific antibodies cross the placenta and enter the fetal circulation where 
they can persist for up to 18 months. Serological HIV assays (antibody tests) are therefore 
unreliable for the diagnosis of HIV infection in infants (they can be useful to determine 
exposure) and virological assays that detect HIV nucleic acids (Nucleic Acid Testing [NAT]) or 
viral antigens (e.g. p24) are required for definitive diagnosis (1, 3). HIV DNA PCR assays are 
routinely used in EID programmes (1). In South Africa, the National Health Laboratory 
Services (NHLS) uses the CAP/CTM total nucleic acid real-time PCR which detects both pro-
viral DNA and RNA of HIV-1. The assay can be performed on dry blood spots (DBS) or EDTA 
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4. Search strategy 
A search of the Medline database via PubMed (National Library of Medicine, Bethesda, MD) 
was performed using the following strategy: 
"hiv"[MeSH Terms] OR "hiv"[All Fields] OR Human Immune Deficiency Virus OR Human 
immunodeficiency virus  
AND PMTCT OR “Mother-to-Child Transmission of HIV” OR “Prevention of Mother to Child 
Transmission of HIV” OR “Vertical Transmission” OR “Vertical Transmission of HIV” 
AND Infant diagnosis OR “Early Infant Diagnosis” OR EID 
AND “Birth Testing” OR “Birth PCR”  
AND "humans"[MeSH Terms] AND English[lang] AND "infant"[MeSH Terms] NOT *toxo NOT 
cmv 
Reports were limited to those published in English from 2008 to present, 2008 being the 
year in which the WHO guidelines were amended (following the findings of the CHER study 
(4)) to recommend treatment of all infants less than 12 months old regardless of clinical and 
immunological stage(20). The search was censored in November 2017. 
Proof of principle and diagnostic assessments and validations of PCR assays, including point 
of care tests, and sampling techniques (e.g. dry blood spots) were excluded, the focus being 
on programmes/studies that incorporated birth HIV-PCR in the EID algorithm; not on the 
sampling or laboratory methods themselves. Reports from high income countries were 
excluded. 
Study selection 
Publications identified by the search were reviewed.  Duplicates were removed and titles 
and abstracts of the remaining articles evaluated.  All articles identified through this process 
were assessed per the objectives specified above. In addition, the bibliographies of reviews 
of EID identified through PubMed were reviewed to identify additional studies (3, 5, 6, 12, 
13, 15, 16, 21-24).  




The search yielded 13 articles published or e-published prior to November 2017 (13, 14, 25-
35). Eight were excluded for the reasons outlined. Two were unrelated to HIV (28, 30); and 
two were evaluations of point of care assays (27, 34).  One reported on the findings of a 
workshop held to evaluate evidence for HIV birth testing for EID (13). One paper reviewed 
an EID pilot programme in Tanzania which did not include birth HIV-PCR (32); nor did the 
VTP programme in Thailand over the period reported by Naiwatanakul et al.(31).  Thailand 
introduced EID on day 1-2 of life in 2015 (13). None of the Thai references identified, 
including those that assessed the elimination of vertical transmission achieved by Thailand 
in 2015, examined EID in detail, focussing more on maternal interventions (36). They were 
therefore not included. 
There were two studies using mathematical models to determine potential benefits and 
costs of HIV birth testing (14, 29). A third modelling study using Brazilian data was excluded 
as this assessed maternal antenatal VTP scenarios with no mention of infant testing 
schedules (25). Of the 13, five papers met the inclusion criteria including the modelling 
studies. (14, 26, 29, 33, 35). A further three were identified by searching the bibliographies 
of reviews (8, 19, 37). No quality criteria were applied for inclusion (Table 1.) 
The two modelling reports are discussed in a separate section below (14, 29). Bibliography 
searches resulted in a further modelling manuscript (38). Two of the modelling studies use 
data from South Africa (14, 29) and the third from sub-Saharan Africa (38). These will be 
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5. Results 
5.1 Study designs, settings and populations 
All six observational studies were based in South Africa (8, 19, 26, 33, 35, 37). In two 
instances, there were two papers reporting different aspects of the same study ((8, 19) and 
(33, 35)). Both these were prospective observational cohort studies at the same study site in 
Johannesburg but at different times and during different VTP guideline periods. The site, an 
urban secondary maternity hospital, had a strong, established VTP infrastructure with 
comprehensive HIV services (antenatal and peri-partum maternal testing, maternal ART, 
infant testing as per the relevant guidelines, and paediatric ART; dedicated staff retested 
women of unknown or negative HIV status postpartum before discharge, including after 
hours and weekend coverage (33).) I will discuss the studies as presented in both papers, 
not the individual publications. 
The remaining two studies report retrospective cohort analyses, one based on a folder 
review from an urban secondary maternity hospital in Cape Town (26); and the other 
aggregate laboratory data from one of the two main HIV testing laboratories in the Western 
Cape (37). The latter included samples from across the centre’s drainage area, including 
primary and tertiary sites, and was not limited to births occurring in a secondary hospital. 
The denominator did not include a sample of HIV-exposed infants in either case; HIV-PCR 
tests were the starting point i.e. HIV-exposed infants who did not receive an HIV-PCR were 
excluded. 
All studies reported positive birth HIV test results and in utero transmission rates, and three 
gave data on subsequent HIV testing (8, 19, 26, 37).  Three provided some measure of 
linkage of HIV infected infants to care (19, 26, 33, 35). The diagnostic and other tests in all 
the studies were performed by the NHLS which serves all the state-run health facilities in 
South Africa. Over the time period in which the studies were conducted (2008 – 2016) the 
national and regional VTP guidelines were updated four times (10, 39-42); the relevant 
recommendations are discussed as applicable.  
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5.2 Study methodology 
The study reported in the papers by Lilian et al. (8, 19) was a prospective observational 
cohort study which enrolled HIV-infected and -exposed mother-infant pairs from the 
postnatal wards at a secondary hospital in urban Johannesburg. Dry blood spot samples 
were collected at birth, two, four and six week visits and stored. Initial HIV diagnosis relied 
on the routine HIV-PCR testing at six weeks old (as per the national guidelines (42)) which 
was performed predominantly at the hospital’s VTP clinic or a related primary clinic 
managed by an HIV NGO (i.e. the six week diagnostic test was not a study procedure).  At 
the end of the project the NHLS national database was searched for any six week HIV-PCR 
tests (and the results) performed on the participants to minimize the missing outcomes. 
HIV-infected infants entered the routine treatment service, again mainly at the paediatric 
HIV treatment clinic at the hospital.  The VTP guidelines at the time, short-course 
antiretroviral treatment, comprised maternal ART if the CD4 count was less than 200 
cells/ml. Women with CD4 counts greater than 200 cells/ml received daily zidovudine (AZT) 
from 28 weeks and single dose nevirapine (NVP) during labour. Infants received NVP at birth 
and four to 28 days of AZT depending on whether the mother received treatment for 
greater than or less than four weeks prior to delivery (42). Exclusive formula feeding was 
supported by the state and NGOs.  Towards the end of the study (April 2010) the guidelines 
were updated raising the eligibility for maternal ART to a CD4 count of less than 350 
cells/ml. ART or AZT were prescribed from 14 weeks gestation and infant prophylaxis 
changed to six weeks of daily NVP. Exclusive breast feeding was now encouraged and 
subsidized formula phased out. 
In the infants identified as HIV-infected by the routine programme, the stored DBS samples 
(with two matched controls) were retrospectively tested using three different nucleic acid 
assays. This allowed for assessment of the technology (8) and timing of infection (19).  This 
study was the first to assess the addition of birth HIV-PCR testing to the routine six week 
algorithm in use in many LMIC and has (despite its limitations) provided much of the 
evidence supporting introduction of birth testing to WHO and South African guidelines (1, 
10). 
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Technau et al. in a prospective cohort study conducted at the same site between June 2014 
and December 2016, assessed a pilot birth HIV-PCR testing programme (33, 35). (Birth HIV-
PCR was introduced in the South African national guidelines in 2015 (10).)  Study counsellors 
enrolled HIV-infected women from the postnatal wards and nurses performed the blood 
sampling. Results were collected by caregivers one week later. The study staff made 
considerable effort to contact the mothers of infants with non-negative (i.e. positive and 
indeterminate) HIV-PCR results and perform follow-up testing as required. Carers of infants 
with negative birth HIV-PCR results were not pursued if they did not collect results. ART for 
infected infants was initiated at the same facility. The South African VTP guidelines during 
this period (10) recommended WHO Option B+ for all HIV-infected women who initiated a 
single daily fixed dose combination tablet comprising tenofovir (TDF), emtricitabine (FTC) 
and efavirenz (EFV). Infants received daily NVP for six weeks and exclusive breast feeding 
was encouraged. By this time subsidized formula was no longer provided at government 
facilities. Initial diagnostic HIV-PCR remained at six weeks until June 2015 (high-risk infants 
were eligible for birth testing) when birth HIV-PCR for all HIV-exposed infants became 
national policy, with a follow-up test at 10 weeks old (10). 
Dunning et al. described a retrospective cohort study of neonates at high risk of HIV 
transmission who received a birth HIV-PCR at a maternity hospital in Cape Town. Those who 
tested negative at birth were matched on date of birth and mode of delivery with HIV-
exposed controls who were not tested at birth.  The NHLS database was searched to identify 
subsequent test results in both groups to compare differences in presentation for follow-up 
testing (at six weeks as per the guidelines (26)) in infants who did and did not receive a birth 
HIV-PCR. The VTP guidelines at the time were the same as those at the start of Technau et 
al., that is, WHO option B+ with birth HIV-PCR indicated only for infants who met high-risk 
criteria for transmission of HIV (40).  
Maritz et al. used aggregate HIV-PCR testing data from the Western Cape NHLS database to 
compare presentation for follow-up testing after birth HIV-PCR during two birth testing 
policy periods (37).  During the earlier period (January 2009 – March 2014) clinicians could 
request a birth test in symptomatic infants. The 2014 Western Cape PMTCT Clinical 
Guidelines Update introduced selective birth testing for those infants meeting high risk 
criteria for transmission (40). This second period (April 2014 – June 2015) overlapped with 
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that reported in Dunning et al. (26). Specific linking software was used to maximize 
probabilistic linkage between birth and subsequent HIV-PCR tests.  
5.3 Participants and sample size 
The sampling populations of both Johannesburg studies included all HIV-exposed infants 
and were not restricted by risk or other categories.  Mothers were, however, required to 
provide informed consent (8, 19, 33, 35). The inclusion and exclusion criteria of the earlier 
study (Lilian et al. 2012 and 2013) further limited enrolment to women who knew their HIV 
status antenatally (i.e. who were not diagnosed during labour or immediately postpartum) 
and who planned to return to the facility for follow-up. Recruitment occurred only during 
working hours. Eight hundred and thirty-eight neonates were enrolled for whom an HIV 
status at six weeks could be determined in 710 (84.7%)(19).  
Technau et al. enrolled mother-infant pairs outside working hours although coverage was 
incomplete. Of 7085 HIV-infected women, 727 (10.3%) were not screened, were ineligible 
(<18 years old) or did not consent.  The median age of testing of 6377 infants was 14 hours 
(33). Dunning et al. identified 575 high-risk neonates who received a birth HIV-PCR. The 551 
with a negative result were matched on date of birth and delivery method with 551 HIV-
exposed infants who did not receive a birth test (despite some presenting with high risk 
criteria)(26). Maritz et al. assessed 3 322 infants with a birth HIV-PCR test, defined as 
occurring within seven days of birth (37). 
5.4 Positive birth HIV-PCR results and in utero transmission 
The proportion of positive birth HIV-PCR results is dependent on the timing and 
effectiveness of VTP ART coverage and the prevalence of risk factors for transmission in 
each study population. The study populations that Dunning et al. and Maritz et al. included 
and tested were high-risk by definition, either meeting specific criteria or being 
symptomatic for HIV infection (period 1 in Maritz et al.).  In addition, Dunning et al. sampled 
a hospital population indicating a level of clinical risk above that of primary care. It is 
unsurprising that the percentages of positive birth tests in these studies are high, 3.8% and 
3.1% respectively. These are higher than the overall transmission rates reported for the 
Western Cape during the period (1.9% before two months old (43)). Of note in Maritz et al. 
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is that the proportion of positive results dropped from 6% in 2009 (symptomatic infants 
tested at the clinician’s discretion) to 1.6% in 2015 as the population eligible for birth testing 
expanded  (routine birth HIV-PCR for all HIV-exposed infants) with a corresponding dilution 
of diagnostic yield/impact (37). In contrast, Technau et al., in a large sample of all HIV-
exposed infants, reported an in utero transmission rate of 1.6% reflecting the reduced 
prevalence in a general population of HIV-exposed infants at all levels of risk(33).   
In the study reported by Lilian et al., in utero transmission was 4.1% (8). This was 
determined by retrospective testing of participant stored birth DBS samples after a positive 
HIV-PCR result at six weeks or older. Transmission is high given broad inclusion criteria (and 
that the high-risk group of newly diagnosed women was excluded) and is probably a 
reflection of shorter and less comprehensive VTP ART strategies at the time (WHO Option A 
(42)). It has been repeatedly demonstrated, most recently in a randomized controlled trial, 
that ART is more effective in preventing vertical transmission of HIV than single or dual 
antiretroviral therapy (44). South African VTP guidelines from 2013 were either Option B or 
B+ thus reducing transmission risk over the periods in which the other studies were 
conducted. 
5.5 Performance of the assays 
As maternal ART and infant post-exposure prophylaxis have become more effective, and 
with the emphasis on very early testing and treatment of infected neonates, concerns have 
been raised regarding the performance of diagnostic nucleic acid assays (9, 39, 40, 45). A 
recent systematic review calculated a pooled sensitivity of 69.3% for birth HIV-PCR in the 
presence of maternal and infant ART although the quality of the evidence was low; 
specificity was more reassuring at 99.9% (quality of evidence intermediate-high) (24). These 
figures included data from the study reported by Lilian et al. (2008-2010; sensitivity 76.3%), 
(8) and data from an earlier French cohort analysis (40) conducted between 1994-2006 
(sensitivity 56.7%). Given the advances in nucleic acid testing technology, the time periods 
are relevant. The authors of the review argued that the low sensitivity reflects the inability 
of birth testing to identify peri-natal infections as opposed to the poor performance of the 
assays themselves (24) which emphasizes the need for additional testing during infancy.  
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One of the concerns highlighted by Technau et al. was the high numbers of errors (0.9%) 
and indeterminate results (0.3%) from birth EID and the additional follow-up and repeat 
testing these necessitated.  An indeterminate result is one that is valid but inconclusive – 
the assay detects the target (e.g. HIV nucleic acid sequence) but the signal is below the 
threshold required to confirm a positive result (46). The proportion of these non-negative 
results could increase with the introduction of point of care (POC) tests which are currently 
less sensitive and more prone to error that conventional laboratory assays (27). It is 
hypothesized that infant post-exposure prophylaxis and maternal ART in breast milk could 
reduce HIV viral load below the detectable levels of routine nucleic acid tests, giving an 
indeterminate or low positive result. While Mallampati et al. found no evidence for this in 
their review, albeit in the face of limited evidence (24), observational studies suggest 
otherwise. Clinicians face the growing challenge of interpreting indeterminate or low-
positive test results (8, 47-49). 
Even in 2008-2010, the single dose NVP and daily AZT infant prophylaxis seemed to affect 
the performance of three diagnostic assays (Lilian et al.)  Some samples (n=4) from the two 
week time point tested negative in individuals infected in utero (i.e. with positive birth and 
six week HIV-PCRs). The authors hypothesized that the infant NVP may be the cause; 
reducing the viral load below the threshold of detectability in all three assays reviewed (8). 
A more recent pooled analysis in non-breastfed populations demonstrated that the type 
and duration of infant prophylaxis did affect time to positivity of HIV-PCR.  The probability of 
a positive birth test was lower if women had received no prophylaxis (but similar at 14 days 
regardless of maternal intervention). This reflects the effect of VTP regimens on intrapartum 
transmissions. i.e. there is a greater proportion of in utero infections (diagnosable at birth) 
in treated women (45). 
In the study reported by Technau et al., considerable resources were dedicated to tracing 
infants with non-negative results and repeated assays were often required to confirm the 
diagnosis. Of 19 infants with indeterminate results, seven (36.8%) ultimately received a 
positive diagnosis, delayed by a median of 30 days; and four (21.0%) infants died before a 
definitive status could be established. Those neonates with a definitive positive HIV-PCR 
result at birth had significantly higher viral loads than those whose initial test was 
indeterminate (35).  A retrospective laboratory data analysis of indeterminate and follow-up 
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HIV-PCR results in infants in Cape Town (median age 45 days), also under Option B+ VTP 
regimens, reported indeterminate rates of 3.2%; 64.1% of infants with initial indeterminate 
outcome subsequently tested positive a median of 28 days later. The study did not report 
on loss to follow-up after the initial indeterminate result (48). Dunning et al. and Maritz et 
al. report the proportion of indeterminate/equivocal birth HIV-PCR results as 0.3% and 1.2% 
respectively (26, 37). Neither discusses these in detail or reports on follow-up results. 
5.6 Return for follow-up testing 
By definition birth HIV testing will only identify in utero infections. While in utero and post-
partum transmission may account for a larger proportion of infant HIV infections than peri-
natal infections under more effective VTP regimens (29, 45), repeat testing during early 
infancy is essential to detect intra-partum and early post-partum infections. The most 
recent iteration of the South African and Western Cape VTP Guidelines (2015; (41)) specify 
repeat HIV-PCR at 10 weeks old following a birth test.  In most of the studies reviewed here, 
a birth HIV-PCR was added to the existing recommended test at six weeks old. 
Loss to follow-up (LTFU) between birth and six weeks has been repeatedly high-lighted as 
compromising the VTP cascade in many settings in the absence of birth testing (3, 16, 23); 
indeed, it is one of the arguments in support of birth testing (9). There is, however, a 
concern that receipt of a negative birth test result may falsely reassure the caregiver 
resulting in reduced presentation for follow-up testing. The risk may be even higher with the 
delay of repeat testing beyond the previously accepted six week time-point. Unfortunately, 
South African data suggest that receipt of a birth HIV-PCR does reduce likelihood of 
receiving a follow-up test (26, 37, 50) and there is concern that the policy may undermine 
the existing part-partum EID service which reached over 80% of exposed infants in 2014 
(12). One EID mathematical model suggests that the cost benefit (in terms of USD per life-
year saved) of adding a birth HIV-PCR to the six week test is lost if more than 37% of 
exposed-infants fail to return for repeat testing (14). 
Lilian et al. report LTFU at six weeks of 17.5% (with telephonic tracing). These participants 
did not receive a birth test result as the stored DBS were tested retrospectively. Ninety-
three percent of those who did present for testing returned for results (26 [4.3%] were HIV 
infected.)  HIV status was established on 19 of those LTFU by testing stored study DBS 
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samples (from birth, two and four weeks). Overall, only 67% of the total number of infants 
tested received results at a median age of 10.6 weeks (19).  It is important to note that this 
comprised a study group, who had consented to participate and who were contacted by 
phone in the event of missed visits. 
The sample reported by Technau et al. also comprised a study population, and only 52% of 
those with negative birth HIV-PCR tests returned to collect the results one week later (35). 
Considerable resources were committed to engaging in care those with non-negative results 
(i.e. positive and indeterminate) and the negative remainder were not followed up. The 
rates of routine HIV-PCR at six or ten weeks were not examined. Those with indeterminate 
results required considerable input. 
In the analysis by Dunning et al. 73% of infants with a birth HIV-PCR presented for routine 
testing at six weeks versus 85% of those with no birth PCR (adjusted OR 0.60 [95% 
confidence interval 0.41 – 0.86]); the risk persisted across demographic and clinical 
subgroups (26). The latter figure (i.e. 85%) is closer to that in the study described by Lillian 
et al. It is relevant to note that in this earlier study (Lilian et al.) women did not receive a 
birth result as samples were tested retrospectively (19) whereas the caregivers hospitalized 
infants reported in Dunning et al. may well have received a negative HIV-PCR result before 
discharge. Maritz et al. report that only 49% of those tested at birth ever received a 
subsequent test, regardless of testing policy; this dropped to 43% if they restricted follow-
up tests within the guidelines window of 6-10 weeks. No non-birth test comparator is 
presented (37). 
Lilian et al. report a transmission rate of 5.4% at six weeks.   In utero transmission was 4.1%. 
When one excludes those testing positive at birth, transmission rate at six weeks was 1.3% 
(8). The drop in in utero transmission four years later (to 1.6%) observed at the same site by 
Technau et al. probably reflects advances in the antenatal VTP programme (33). 
In the cohort presented by Dunning et al. testing at the six week time point yielded a far 
lower proportion of positive results regardless of whether a birth HIV-PCR had been 
performed or not, 0.5% and 0.4% respectively (26), demonstrating the high yield with 
targeted birth testing. Those infants who tested positive at birth were excluded from the 
later test and those not tested at birth were more likely to be at lower risk of transmission. 
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The latter two studies are limited in that they are unable to ascertain reasons for LTFU, 
particularly mortality. Under the discretionary and high-risk testing policies, infants 
receiving HIV-PCR at birth were more likely to be born in hospital or referred immediately 
after birth and by definition met high-risk criteria including clinical symptoms, low birth 
weight and prematurity all of which increase neonatal mortality. It is likely that a proportion 
of those LTFU may have died (from any cause) before repeat testing. (Both Johannesburg 
studies report deaths prior to diagnosis and ART (19, 35)).  
5.7 Linkage to HIV care 
Three studies discuss linkage of HIV-infected infants to care (19, 26, 35).  One of the key 
findings reported by Lilian et al. which has been used to promote birth HIV testing agenda 
was that an initial test at six weeks old resulted not only in loss to follow-up of in utero 
infected infants but in delayed initiation of ART in those following the EID algorithm at the 
time (median age at ART start, 16 weeks). (The initial CHER findings, recommending early 
infant ART before seven weeks old (4) and the Bourne data demonstrating the peak in South 
African infant mortality at 2-3 months old (50) were published early in the course of the 
study. i.e. there was increasing awareness of the high early mortality of infant HIV infection 
and that early diagnosis and treatment could reduce this.)  Four infants were LTFU between 
diagnosis and ART, and six died, three soon after initiation.  Only 37% of HIV positive infants 
remained in care at one year, but the majority were virally suppressed. There was 
considerable attrition after starting ART (19).  
Dunning et al. did not discuss time to ART but reported viral suppression (which was 
determined from NHLS laboratory results). Eighty-six percent of neonates diagnosed at birth 
had evidence of ART versus 100% if the first HIV-PCR occurred later (there were only four in 
this group). Again it is not clear whether the attrition was due in part to mortality in the 
birth group. Infants who received a birth test took longer or failed to achieve viral 
suppression (26). This may be due to viral dynamics and the timing of infection (i.e. in utero 
versus peri-partum); or to social factors which could influence both transmission risk (e.g. 
associated with limited or no antenatal care or ART) and infant ART adherence. 
In Technau et al., active outreach for infants with non-negative birth HIV-PCR tests ensured 
that 96% of infected infants were traced and initiated on ART, the majority within a median 
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of eight days at the hospital.  Extra staff were required for outreach, counselling and 
administration. An additional seven infants (7.1%) were confirmed as having initiated 
treatment at other sites between 40-99 days (considerably older)(33). 
A retrospective study in the Western Cape between 2005 and 2011 using laboratory data to 
link positive HIV-PCR results to subsequent viral load assays (viral load as a marker of having 
attended for HIV care) found that 65% of infected infants received at least one follow-up 
visit. By 2010 this was 71% with a median time to follow-up of 33 days. The sample here is 
larger comprising 6 322 infants (51). 
5.8 Modelling the timing of Early Infant Diagnosis 
Faced with operational challenges and attrition of exposed infants from EID programmes, as 
well as the clinical consequences of missed or delayed diagnosis of vertical HIV infection, 
and with therapeutic, technological and programmatic advances, several groups have 
presented mathematical models to inform optimal time-points for EID in LMIC. Since 
virological assays are expensive and birth PCR necessitates additional testing time-points, 
much of the focus has been based on cost relative to diagnoses made and life-years saved. I 
identified three papers that modelled alternative EID testing strategies and will discuss 
these here (Table 2).  Two models were based on South African data (14, 29) and the other 
used data from sub-Saharan Africa then applied the model to Kenya and Swaziland 
specifically (38). All used laboratory-based nucleic acid assays for diagnosis, with the 
attendant delays. The introduction Point of Care (POC) testing may impact the models’ 
projections: since results are available within hours the prolonged turn-around times (TAT) 
sending samples from testing site to laboratory and results back to the site would become 
irrelevant. However, assumptions regarding the sensitivity and specificity of laboratory-
based nucleic acid assays cannot be applied to POC tests. 
The studies differed in terms of specific research questions and objectives, and in terms of 
the design and level of complexity of the mathematical model applied.  
Lilian et al. is the earliest published attempt to model birth HIV-PCR testing (29).  They 
present an individual-based stochastic model designed to simulate antiretroviral 
prophylaxis, infant feeding and health outcomes in 240 000 HIV-exposed infants. An 
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individual-based model can accommodate changes in the parameters over time and is 
better able to simulate long term outcomes (as opposed to a decision-tree analysis, for 
example [see Chiu et al. (38)]). The study aimed to identify the EID strategy that would 
maximize the number of in utero and peri-natal HIV infections diagnosed and number of life-
years saved; and to highlight any programmatic concerns that might impact on diagnosis. 
The standard assumptions were based on the 2010 South African VTP guidelines (WHO 
option A; (41)) although option B was modelled as one scenario. Rates of HIV-PCR uptake 
were based on South African sources and the sensitivity of HIV-PCR at six weeks old was 
assumed to be reduced in the context of prolonged daily NVP prophylaxis. A single HIV-PCR 
at different time points (birth, six, 10 or 14 weeks) and two HIV-PCRs (birth and six, 10 or 14 
weeks) were compared.  A single birth HIV-PCR offered no advantage over single test at six 
weeks old in terms of number of diagnoses made.  A single test at 10 weeks old maximized 
the number of HIV-infected infants identified but did not save additional life-years when 
compared to a single birth test (owing to death before diagnosis at 10 weeks). When two 
PCR tests were considered, testing at birth and 10 weeks old were superior to a single test 
at six weeks (under the guidelines at the time) with a 30% increase in HIV diagnoses and 
61% increase in life-years saved. This advantage remained under different feeding and VTP 
programme scenarios. Cost-effectiveness analysis was not performed (29). 
Francke et al. also used an individual-based model and South African data (14). Their 
standard parameters were based on the 2015 South African VTP guidelines (WHO Option 
B+; (10)) and assumed expanded ART coverage in pregnant women and 80% breastfeeding 
prevalence.  The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Pediatric 
model was used to compare four EID testing strategies:  no EID; a single HIV-PCR at birth or 
six weeks; and two HIV-PCRs at birth and six weeks. The CEPAC-Pediatric model is an 
adaptation of the microsimulation model of pediatric HIV disease expanded to account for 
transmission and diagnosis. It is a complex model able to accommodate infants from birth to 
death. Survival, HIV-related healthcare costs and life expectancy were used to calculate the 
incremental cost-effectiveness ratio (ICER) for each EID strategy. When a single HIV-PCR 
strategy was assessed, the six week time-point was more effective clinically and in terms of 
cost than birth. Cost effectiveness per life-year save favoured birth and six weeks testing 
above six week time-point alone. But, survival benefits were lost if 37% of infants did not 
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return for follow-up testing; and increasing the proportion of results returned and HIV-
infected infants linked to care with the single test at six weeks had a greater impact on 
survival than the addition of a birth test. The authors recommended strengthening the six 
week testing programmes before the addition of the birth HIV-PCR (14). 
Chiu et al. used the least complex model (Microsoft Excel decision-tree model) to evaluate 
the benefit of adding an HIV-PCR at birth to the existing six week time-point for 1 400 000 
HIV-infected pregnant women and their infants in sub-Saharan Africa (38). This differs from 
the South African studies in scale and range: antenatal HIV prevalence, maternity and infant 
care infrastructure, proportion of facility-based births, and HIV and VTP treatment 
programmes vary widely across the region.  Sensitivity analyses were therefore performed 
using low and high estimates of facility-based births, VTP strategies and uptake, and infant 
testing. The model was also applied under two country-specific conditions, Kenya and 
Swaziland.  The outcome (benefit of addition of a birth test) was assessed as the number of 
HIV-infected infants initiated on ART by three and 18 months and the number of HIV-related 
deaths prevented at 12 months. Addition of a birth HIV-PCR increased the number of infants 
on ART at three and 18 months with a corresponding increase in survival. Not surprisingly, 
the rates of facility births and enrolment of infected infants into HIV care had the biggest 
impact on the birth testing strategy. Even with a facility birth rate of 43%, the number of 
infants on ART at three months increased by 543% with birth HIV-PCR. Uptake of VTP 
services was also important – the poorer the uptake, the greater the rates of transmission 
and the greater the impact of birth testing in diagnosis and referral for ART. Thus addition of 
a birth HIV-PCR would have the greatest effect in settings with low rates of VTP uptake and 
high rates of facility births (the country example of Kenya in this study.) 
All mathematical modelling studies are limited by the chosen model’s assumptions. These 
are based on the available data which in the field of VTP may soon become outdated. Lilian 
et al. based their analysis on the South African 2010 VTP guidelines; Francke et al. on the 
2015 iteration. Assumptions of HIV-PCR assay sensitivity at different time-points may be 
inaccurate in the face of prolonged in utero and postnatal exposure to ART. Point-of-care 
HIV-PCR assays will reduce (eliminate) turnaround time for results but may compromise 
sensitivity. The predictions of the models are context specific. Cost effectiveness of two HIV-
PCRs, birth and six or 10 weeks, is dependent in the risk of vertical transmission, rates of 
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linkage of infected infants to care and attrition of infants who tested negative at birth and 
who fail to return for follow-up testing. Given the high rates of facility-based births in South 
Africa the data may not be generalizable in other contexts; a point highlighted by the 
findings of Chiu et al (38). 
5.9 VTP implementation gaps highlighted by the literature 
While documenting significant improvements in VTP programmes, reduced transmission of 
HIV and improved access to care, the papers reviewed highlight persistent gaps as well as 
newer challenges. The majority of infants tested were born at hospital. Both Rahima Moosa 
Mother and Child Hospital in Johannesburg (8, 19, 33, 35) and Mowbray Maternity Hospital 
in Cape Town (26) have well-established and maintained VTP programmes. Even when 
looking at the aggregate data (37), despite the greater than 20-fold increase in the number 
of birth HIV tests performed when high risk testing introduced in 2014 in the Western Cape, 
the majority of these tests were done at obstetric hospitals (74%). How such systems 
operate at primary care facilities and in rural areas is unknown but they are unlikely to be as 
well-resourced or as efficient. 
Despite the robust VTP infrastructure in Johannesburg and the resources attendant to the 
cohort studies, attrition remained significant in the absence of ‘active outreach’ (telephone 
calls and home visits; K Technau, personal communication). Highlighted in all studies, is the 
fragmentation of health care in South Africa and the uneven distribution of skills and 
resources. Routine infant immunization and care (and VTP follow-up) occur neither at 
hospitals nor at the midwife obstetric units (MOU) which offer primary care delivery 
services. Carers are directed to local clinics which are often managed by a different branch 
of government; there are limited electronic medical records systems at the sites and patient 
identifiers can be multiple and fluid. Identification of HIV-exposed infants is usually 
dependent on caregiver report or completion of the Road to Health Book, a client-retained 
record of growth, immunizations and clinic visits. Concerns of inadvertent disclosure and 
stigma undermine accurate completion of these books (43). Given that birth HIV-PCR 
detects only in utero infections by definition, repeat testing at 10 weeks is essential. The 
projected savings (in terms of cost and life-years) achieved by the introduction of birth 
testing will be undermined by failure to present for follow-up (14). 
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Both Western Cape studies suggest that targeted birth HIV-PCR may undermine the follow-
up repeat testing (26, 37). Unfortunately Technau et al. did not examine this. It is possible 
that the contributors to the high risk indications for birth HIV-PCR in these studies are the 
same factors that influence return to care post-partum. That is, that the same women who 
demonstrated poor health seeking behaviours antenatally (present late or not at all for 
antenatal care; were tested late in pregnancy and received ART for limited periods; failed to 
suppress on treatment; or may have had lifestyles that put them at risk for premature 
labour and low birth weight infants – smoking, alcohol use, other illnesses) found difficulty 
in managing the follow-up requirements for their infants.  The introduction of universal birth 
testing of HIV-exposed neonates may re-adjust the numbers presenting for repeat testing 
after receipt of a negative birth HIV-PCR. It is likely however, that a group of women will 
remain at high risk of vertical transmission despite improvements in the VTP programme 
and the factors, many of them social and economic, that place them at risk of transmission 
are the same ones that compromise the health care of their babies. 
There is continued debate at to the optimal timing of infant HIV testing particularly in 
resource limited settings where the cost of the virological assays can be prohibitive. The 
modelling studies have attempted to address this. The South African Department of Health 
has committed to funding two early HIV-PCRs (10). With the high rate of facility-based 
deliveries, models suggested tests at birth and 10 weeks would be optimal. However, 
Technau et al. demonstrated considerable human resources devoted to follow-up not only 
of infants with positive birth HIV-PCR results but also those with indeterminate results. 
These infants required numerous repeat tests contributing to additional costs (35). These 
data appeared too late to be included in the modelling analyses. An early (2004 – 2010) 
South African study of 718 children with unconfirmed positive HIV-PCR tests found 40 to be 
negative giving a positive predictive value for the HIV-PCR in children under 18 months of 
94.4%. The authors demonstrated loss of positive predictive value as MTCT rates decreased 
i.e. prevalence of vertically infected infants decreased (44).  More recently, Maritz et al. 
using a dataset of 38 043 first HIV-PCR results demonstrated that the proportion of non-
negative results reported as indeterminate decreased as VTP regimes intensified (11.5% 
under the current Option B+ guidelines) and that more indeterminate infants tested positive 
on repeat testing (48). This was also the case in Technau et al (35). 
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Apart from Maritz et al. who used aggregate laboratory data, all the studies presented were 
based at urban maternity hospitals with established VTP programmes. The two prospective 
studies were limited to the same site in Johannesburg. Generalizing these findings to South 
Africa more broadly may be inappropriate. They offer no insight into how the system would 
operate in the primary care setting or in rural areas.  
5.10 Methodological challenges in the literature 
Both prospective studies were based at the same centre and the samples could be biased 
towards women attending such a large urban facility (8, 19, 33, 35). Birth testing coverage 
was high due to project resources. Caution should be exercised in generalizing the results. In 
addition, both were subject to losses to follow-up and it was not possible to determine the 
proportion of LTFU due to death. The study report by Lilian et al. was biased towards 
identification of in utero diagnosis since all birth specimens were available but later 
sampling was incomplete (19). 
Both Dunning et al. and Maritz et al. relied on laboratory data accessed through the NHLS 
and/or archived in the NHLS Corporate Data Warehouse. The NHLS performs all pathology 
tests in the public sector in South Africa representing approximately 80% of the population 
(12). Data from these sources are dependent of the quality of routine entry. Nationally, the 
NHLS data lack unique identifiers making de-duplication difficult. i.e. it is not possible to 
accurately determine the number of individual infants tested, only the number of tests.  
Some individuals may be counted more than once and true vertical transmission risk cannot 
be determined; the total number of HIV-exposed infants is unknown and cannot be used as 
the denominator. (12). This problem is less apparent in the Western Cape (Dunning et al. 
and Maritz et al.) where there has been an attempt to implement the use of unique 
identifiers throughout the Provincial health services. However, the system is not faultless; in 
addition, there is often a delay in issuing the infant unique numbers and HIV-PCR may be 
recorded under the maternal identifier. Although Maritz et al. made use of sophisticated 
linking software (37) they did present aggregate data.  
The limitations of the mathematic models are discussed above (Section 5.8).  
6. Limitations of the review 
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Given the recent introduction of birth HIV-PCR programmes in LMIC there are limited data 
available on the impact of such strategies in routine settings. Assessments are limited to 
South Africa where birth HIV testing of high-risk infants has been recommended since 2013 
(with admittedly limited implementation) and routine testing of all exposed neonates 
included in the 2015 VTP guidelines (10). No studies have assessed the impact of birth 
testing strategies, (in terms of guideline adherence and operational impact) in primary 
health settings, all have been urban hospital-based where women are unlikely to be 
discharged within hours of delivery as occurs at primary facilities. South Africa has high rates 
of institutional deliveries (52) and an efficient laboratory network in the urban areas. 
Operational data on the implementation in rural areas is lacking. 
The search was restricted to articles in English catalogued on PubMed. This excluded 
potential studies in LMIC where English is not the historical medium of research (Brazil, 
Russia). It was difficult even to determine the EID testing regimen in Brazil (not attempted 
for Russia). 
7. Areas for further research 
This review identified the following under-researched areas: 
1. The extent to which guideline recommendations are implemented in different settings 
(e.g. urban/rural; different levels of care.) 
2. Assessment of the (unanticipated) resource and cost implications of follow-up and repeat 
testing in those infants with indeterminate non-negative birth HIV-PCR results. 
3. Whether follow-up repeat HIV-PCR testing at 10 weeks old improves as the new 
guidelines become routine at facilities and why infants to do not receive this test. What 
strategies could be implemented to improve fidelity with the VTP testing guidelines? 
4. On-going appraisal of linkage to care (and ART initiation) of HIV-infected infants. 
5. With a view to the elimination of MTCT in South Africa, assessment of associations and 
risks that predict ongoing vertical transmission in the context of option B+, and possible 
interventions. 






It is possible to implement routine birth HIV-PCR testing of all HIV-exposed neonates in a 
large urban secondary hospital in South Africa. Within this context, ART initiation is indeed 
expedited. However, effective implementation required increased human resources and 
enhanced record keeping.  Indeterminate results are not uncommon and require additional 
resources for follow-up and repeat testing. This should be considered in future cost 
analyses.  In the context of the current South African VTP programme infants indeterminate 
results require follow-up and the majority will be confirmed HIV-infected. 
The literature highlights the difficulties arising from the fragmentation and historic 
underfunding of the South African health care system: incomplete records, lack of electronic 
linkage, failure to communicate and follow policy. 
9. Postscript: publications subsequent to November 2017 
Prior to submission of this dissertation but after November 2017 an additional relevant 
article was published ahead of print (53). Moyo et al. draw on NHLS aggregate HIV-PCR 
testing data for the whole of South Africa to assess the first year of implementation of the 
birth HIV-PCR for all HIV-exposed infants policy. They report that monthly birth tests 
increased from 39% to 93% between June 2015 and May 2016, with a rapid drop in the 
number of six week tests (from 82% to 19%) and only a modest rise in 10 week testing (from 
13% to 48%).  This would seem to confirm the Western Cape findings discussed above that 
the introduction of an HIV-PCR test at birth has undermined the required follow-up testing 
(26, 37). The authors believe that the poor uptake of the 10 week test is due to poor 
implementation of the new VTP guidelines since attendance of the 10 week immunization 
visit is high (53). This loss to the VTP continuum (52%) is well above the modelling threshold 
for loss to follow-up testing (37%) over which addition of a birth HIV-PCR ceases to be cost 
effective (14).  
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With the increase in sample size the number of positive HIV-PCR tests declined with an in 
utero transmission rate of 1.1%. The high rates of HIV infection in pregnant women mean 
that the absolute number of HIV-infected infants remains high (247/100 000 live births) 
despite the low transmission rate (53).  
The limitations of the NHLS database are described above (section 5.10). In addition the 
authors had to estimate the numbers of HIV-exposed infants (the denominator), based on 
maternal antenatal HIV infection rates in order to assess coverage of birth tests. While 
results are presented by province there are no data on the urban/rural or primary versus 
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2. Abstract  
Introduction: To strengthen the early infant diagnosis (EID) programmes and timeously 
identify and treat HIV-infected infants, birth HIV-PCR has been recommended in the 
Western Cape, South Africa since 2014. Operational data on the implementation of such 
programmes in low- and middle-income countries are limited. 
Methods: Utilizing the electronic records platform at primary care facilities, we developed 
an electronic register which consolidated obstetric and HIV-related data, allowing us to track 
a cohort of HIV infected/exposed mother/infant dyads longitudinally from antenatal care 
through delivery to infant HIV-PCR. We assessed guideline implementation and impact on 
EID during three periods reflecting sequential EID policies in a referral chain of facilities in 
Cape Town (primary to tertiary care). Birth HIV-PCR was indicated in period 1 if 
symptomatic; period 2 if meeting high-risk criteria for transmission; and period 3 for all HIV-
exposed neonates. 
Results: We enrolled 2012 HIV-exposed infants; the majority (89.2%) had at least one HIV-
PCR. The proportion tested at 6-10 weeks old dropped from 92.9% during period 1 to 80.2% 
in period 3. The proportion of infants receiving birth HIV-PCR increased, peaking at 60.5% 
during period 3. The majority of birth tests were performed in hospital versus primary care 
regardless of policy period. Almost half of all infants (47.9%) had at least one high-risk 
criterion for vertical infection; of these, 39.7% had a birth test. Infants with more risk factors 
were more likely to have birth EID. Receipt of a birth HIV-PCR significantly reduced the 
likelihood of receiving a follow-up test at 6-10 weeks, even after adjusting for potential 
confounders (aOR 0.18 [0.12 – 0.26]). The proportion of positive birth tests was highest 
(2.9%) when birth tests were restricted to infants meeting high-risk criteria, with a low 
proportion positive for the first time at 6-10 weeks. During period 3, the proportion positive 
at 6-10 weeks was high (2.4%), highlighting the importance of follow-up to detect intra-
partum and early post-partum infections. 
Conclusions: Over all policy periods, EID guidelines were incompletely implemented across 
all levels of care but especially in primary care. Birth HIV PCR reduces return for follow-up 
testing which is critical for the effectiveness of the programme. 
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3. Introduction  
The introduction of birth HIV-PCR for HIV-exposed infants as part of early infant diagnosis 
(EID) has been promoted as a means of maximizing the effectiveness of EID programmes by 
increasing testing coverage, and identifying in utero HIV-infected neonates allowing early 
initiation of antiretroviral therapy (ART)(1). The World Health Organization (WHO) included 
a conditional recommendation in the 2015 vertical transmission of HIV prevention (VTP) 
guidelines for a diagnostic nucleic acid test around birth (0-2 days), in addition to routine 
HIV testing at 4-6 weeks, either for all HIV-exposed infants or for those determined to be at 
high risk of vertical infection (targeted birth testing)(2). 
It has been suggested that birth HIV-PCR will address some of the shortcomings of the 4-6 
week testing time-point which is standard in many VTP programmes in low- and middle-
income countries (LMIC). In 2015 operational delays with attrition at all points along the EID 
continuum, resulted in only an estimated 51% of HIV-exposed infants receiving an HIV-PCR 
before two months old in the WHO 21 priority countries (3).  Even fewer initiated ART (4). 
Modelling studies suggest that the addition of birth HIV-PCR to testing algorithms would 
increase the number of infants diagnosed with HIV and therefore life-years saved (5, 6).  
Since birth HIV-PCR cannot detect infections due to intra-partum and post-natal 
transmission, a subsequent early HIV test would be required (e.g. at 6-10 weeks). Indeed, 
models suggest that the clinical benefits of adding birth HIV-PCR may be eliminated if loss to 
follow-up (LTFU) at subsequent testing times is 37% (5). Given the cost implications of 
additional nucleic acid assays and the often poor implementation of current EID guidelines, 
there is debate as to the optimal number, and timing, of infant diagnostic tests (7, 8). This 
has prompted calls for operational data to evaluate birth HIV testing in routine settings in 
LMIC (7). 
In 2015, the South African (SA) National Department of Health introduced birth HIV-PCR for 
all HIV-exposed infants, with a second test at 10 weeks old, becoming the first national 
programme to do so in sub-Saharan Africa (9).  In the Western Cape a policy of targeted 
birth testing had been implemented since August 2014. 
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We aimed to examine the uptake of infant HIV testing under three different EID policies in a 
referral chain of facilities in Cape Town (from primary care to district, secondary, and 
tertiary level hospitals) using prospective, longitudinally-collected individual patient data. 
We assessed adherence to provincial EID guidelines, the yield of HIV-PCR at birth at the 
sites, and the impact on presentation for follow-up testing.  
4. Methods  
This study formed part of an implementation science project aimed at assessing VTP 
coverage and effectiveness with an active surveillance system in the form of an electronic 
register (e-register). Using the digitized medical record platform in primary care facilities, 
the e-register prospectively consolidated routinely collected clinical data from paper-based 
obstetric and HIV registers. HIV-associated laboratory data and ART prescriptions were 
integrated. 
Setting and Participants 
This was a prospective cohort study of HIV-exposed live infants of women who attended 
antenatal care and/or delivered at Mitchell’s Plain Midwife Obstetric Unit (MPMOU), an 
urban primary care facility, and its referral centres in Cape Town, SA. Uncomplicated vaginal 
deliveries were managed by midwives at MPMOU. Approximately half of all women were 
referred to hospital either during pregnancy or intra-partum. MPMOU referred to Mitchell’s 
Plain District Hospital (with operating theatres), Mowbray Maternity Hospital (level 2 with 
neonatal ICU facilities), and Groote Schuur Hospital (level 3 with adult and neonatal ICU 
facilities) based on standardized criteria. 
Between February 2014 and December 2015, all women presenting to MPMOU for 
antenatal care with an expected or actual delivery date before June 2016, regardless of HIV 
status, were enrolled. Women who presented for the first time in labour (i.e. received no 
antenatal care) were enrolled until June 2016. Deliveries were followed through December 
2016.  
WHO Option B+ was the VTP policy in place over the study period (10-12). Women of 
negative/unknown HIV status were offered HIV testing (rapid assay) at their first antenatal 
visit, during the third trimester, and during labour/immediately post-partum. HIV-infected 
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women initiated life-long ART. HIV-exposed infants received 6-12 weeks of daily nevirapine 
not. In 2015, these guidelines were amended so that neonates at low risk of vertical 
transmission received six weeks of NVP, whereas NVP was extended to 12 weeks for high-
risk infants with zidovudine added for the first six weeks (10). 
EID Testing Periods 
The Western Cape EID guidelines changed twice during the course of the study, giving three 
EID policy periods (10-12). During period 1 (May 2013-July 2014), birth HIV-PCR was offered 
in addition to the routine six-week test at the discretion of the clinician where there was 
clinical suspicion of HIV infection (11). During period 2 (August 2014-November 2015), 
additional birth HIV-PCR was indicated in the presence of defined high-risk criteria for 
vertical transmission (Table 1)(12). During period 3 (from December 2015) birth HIV-PCR was 
indicated for all HIV-exposed infants regardless of transmission risk, with an additional test 
at 10 weeks old in place of six weeks (10).  
Maternal Factors Infant Factors 
Diagnosed with HIV after 28 weeks gestation Born before 37 completed weeks of gestation 
HIV seroconversion during pregnancy Birth weight below 2500g 
Less than 12 weeks of ART before delivery  
Plasma viral load greater than 1000copies/ml  
Table C.1. High risk criteria for vertical transmission of HIV(12) 
Procedures and Measurements 
The e-register provided a single longitudinal record for each mother-infant dyad and 
included HIV testing and ART history from first antenatal visit through to infant HIV-PCR with 
database closure in June 2017. Results of maternal viral load (VL) performed during 
pregnancy or within two weeks of delivery were included. A woman was considered to 
seroconvert during pregnancy if she tested positive for HIV after an initial negative 
antenatal result. Infant HIV-PCR tests were deemed “birth tests” if they occurred within 
seven days of birth and as “6-10 week tests” if they occurred between four and 14 weeks 
old. This window included the follow-up testing time-points across all periods. 
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Linking maternal and infant data 
According to standard procedures at MPMOU, key delivery elements were entered by 
midwives onto a digitized medical records system generating an infant identifier which 
linked the mother-infant pair. A linked infant folder number was similarly generated at the 
hospitals. The sample was limited to those mother-infant pairs that could be linked (96.6% 
live-born HIV-exposed infants in the cohort). 
Analysis 
Analysis was performed using STATA v.15.0 (Stata Corporation, College Station, Texas, USA). 
Continuous variables were summarized using means and confidence intervals (CI) or 
medians and interquartile ranges (IQR) for normally and non-normally distributed variables 
respectively. Categorical variables were described using proportions, and frequency tables 
used for comparison. Significance was tested using a two-sample t-test or Wilcoxon rank-
sum test 
test for categorical data.  The predictors of follow-up HIV-PCR were assessed using logistic 
regression. Multivariate models were fitted including known or suspected risk factors for 
the primary outcomes. 
Ethics  
The study was approved by the University of Cape Town Human Research Ethics Committee 
and the Provincial Government of the Western Cape Department of Health Research. 
A waiver of consent was granted for the e-register since the data were collected as part of 
routine care by the health services and entered on the provincial medical records platform 
falling within formal protection policies. 
5. Results  
We included 2012 HIV-exposed infants, 272 (13.5%) in period 1, 1391 (69.1%) in period 2, 
and 349 (17.4%) in period 3. The proportion of infants receiving birth HIV-PCR increased 
over the study period with rapid increases following guideline changes (Figure 1). Median 
age at birth HIV-PCR was zero days (IQR 0 – 1.4). 
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Figure C.1. The number of HIV-exposed infants and the percentage receiving birth HIV-PCR 
during the three policy periods. Change in EID policy is indicated by the black arrows. 
Generation of infant numbers at MPMOU was poor at the start of period 1, affecting linkage 
of infants and their mothers. Some exposed neonates were therefore not included. Few 
infants were born to enrolled women after March 2016 (antenatal recruitment having 
ceased in December 2015). 
Risk factors  
Over the study period, 47.9% of mother-infant pairs had at least one risk factor for vertical 
HIV transmission (Table 2). Viral load was >1000 copies/ml in 201 (14.9% of the 1346 
(66.9%) women in whom VL was available.) The number of risk factors per infant remained 
stable over time but the proportion of HIV-exposed infants whose mothers were diagnosed 
with HIV during pregnancy (including seroconversion) decreased from 3.7% in period 1 to 
1.4% in period 3. Similarly, the proportion of women who received <12 weeks of ART prior 
to delivery dropped: 28.3% in period 1, 21.5% in period 2 and 12.6% in period 3. Time on 
ART prior to delivery increased from a median of 20.1 weeks (IQR 10.6–39.9) to 21.1 weeks 
(12.1–85.7) and 25.3 weeks (12.6–88.9), in periods 1-3 respectively. By mid-2016, over 40% 
of HIV-infected women had conceived on ART. The percentage of infants born <37 weeks 
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gestation or with birth weight <2500g remained stable over periods 2 and 3 (6.7% and 5.2%, 
and 14.1% and 12.3%, respectively) but was lower in period 1 (1.5% and 7.0%). 
The proportion of infants receiving birth HIV-PCR increased from 11.8% in period 1, to 34.5% 
in period 2 and 67.4% in period 3. Over the study period, 39.7% of babies with one or more 
high-risk criterion received birth EID. The association between having a high-risk criterion 
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Facility of Birth 
The majority of the infants (41.7%) were born at MPMOU with the numbers dropping as the 
level of care increased (Table 3). At all sites, the proportion of HIV-exposed infants receiving 
birth HIV-PCR increased with the guideline changes. Most of the birth tests were performed 
in hospital and not at the primary care site, even in period 3. 
 
Table C.3. The proportion of infants with birth HIV-PCR born in each facility per policy 
period MPMOU – Mitchell’s Plain Midwife Obstetric Unit; MPDH – Mitchell’s Plain District 
Hospital (level 1); MMH – Mowbray Maternity Hospital (level 2); GSH – Groote Schuur 
Hospital (level 3); Other – MOUs and hospitals in the Western Cape outside the study 
facilities. 
Timing of HIV-PCR and follow-up testing 
1794 (89.2%) HIV-exposed infants had at least one HIV-PCR, 88.1% (1580) at 6-10 weeks 
(Table 4). This dropped from 92.9% of infants having HIV-PCRs at six weeks in period 1 to 
80.2% in period 3. No HIV-PCR result could be found for 218 (10.8%) infants; death was 
confirmed in three of these. Among 656 infants who tested HIV-PCR negative at birth, 526 




Facility total n=2012 period 1 n=272 period 2 n=1391 period 3 n=349 




MPMOU 838 (41.7) 150(17.9) 126(46.3) 6(4.8) 548(39.4) 87(15.9) 164(47.0) 57(34.8) 
MPDH 
(level 1) 
710 (35.3) 301(42.4) 83(30.5) 1(1.2) 520(37.8) 207(39.8) 107(30.7) 93(86.9) 
MMH 
(level 2) 
343 (17.1) 141(41.1) 59(21.7) 20(33.9) 235(16.9) 82(34.9) 49(14.0) 39(79.6) 
GSH  
(level 3) 
98 (4.9) 61(62.2) 3(1.1) 1(33.3) 75(5.4) 46(61.3) 20(5.7) 14(70) 
Other 23 (1.1) 14(60.9) 1 0 13(0.9) 6(46.4) 9(2.6) 8(88.9) 
All 
facilities 
2012 667(33.2) 272(13.5) 28(10.3) 1391(69.1) 428(30.8) 349(17.4) 211(60.5) 
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 total n=2012 period 1 n=272 period 2 n=1391 period 3 n=349 
At least one HIV-PCR n (%) 1794 (89.2) 238 (87.5) 1242 (89.3) 313 (89.7) 
Single HIV-PCR only* 1149(64.0) 182(76.5) 829(66.7) 138(44.1) 
Age first PCR, weeks median (IQR) 6.0 (0.1 – 6.6) 6.3 (6.0 – 6.9) 6.1 (0.1 – 6.6) 0.1 (0 – 6.1) 
Birth HIV-PCR present n (%) 667 (37.2) 28 (11.8) 428(34.5) 211 (67.4) 
6-10 week HIV-PCR present* n (%) 1578 (88.1) 221 (92.9) 1106 (89.8) 251 (80.2) 
Follow-up HIV-PCR ever after birth 
test* n (%) 526 (80.2) 21 (77.8) 337 (80.8) 168 (79.6) 
Age F/U HIV-PCR*, weeks median 
(IQR) 6.5 (6.1-8.3) 6.3 (6.1 – 6.6) 6.4 (6.0 – 7.1) 8.6 (6.4 – 10.7) 
HIV-PCR positive ever n(%) 32 (1.8) 1 (0.4) 25 (2.0) 6 (1.9) 
Overall transmission rate 1.8 0.4 2.0 1.9 
In utero transmission rate (95% CI) 1.7 (0.8-2.9) 3.6 (0.1-19) 2.3 (1.1-4.3) 0  
Detection rate at 6-10 weeks* 
(95% CI) 
0.6 (0.3-1.0) 0  0.5 (0.1-1.1) 2.3 (0.9-5.1) 
Median (IQR) age HIV-PCR 
positive, weeks  
6.4 (0.4 – 40) 0.1 6.0 (0.1 – 40.1) 6.8 (6.4 – 12) 
Table C.4. Timing of HIV-PCR by policy period and HIV transmission.  
*denominator excludes those with positive birth HIV-PCR 
HIV transmission 
HIV transmission in all infants for whom an HIV-PCR result was available was 1.8% 
(32/1794). This included in utero, intra-partum and post-partum infections (Table 4). The 
median age of HIV diagnosis was 6.4 weeks. The in utero transmission rate (i.e. proportion 
of infants with birth tests in whom HIV infection was detectable at birth) was 3.6% in period 
1 (n=1) and 2.3% in period 2. There were no positive birth HIV-PCR results in period 3. 
Overall, 34.4% of all HIV infections were identified at birth – the proportion being highest in 
period 2 (40%). In period 3 100% of HIV infections were detected at six-weeks or later. 
Of all birth HIV-PCRs (n=667), 11 (1.7%) were positive, 654 (98.0%) were negative, and two 
were indeterminate (0.3%). Both of these infants tested negative on repeat assays, at eight 
weeks and 6.1 weeks. Eleven (0.7%) infants were identified as HIV infected at the 6-10 week 
time-point, 1553 (98.4%) tested negative and 15 (0.9%) indeterminate. Of the latter, all but 
one for whom no further results could be found were negative on subsequent testing. Five 
of the 11 infants first identified as HIV infected at 6-10 weeks had had a negative birth HIV-
PCR indicating intra-partum or early post-natal transmission. 
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Seven of 450 infants (negative/unknown status) who had HIV-PCR after 14 weeks old were 
HIV-infected giving a detection rate of 1.6% at this time-point (median age at diagnosis 51.2 
weeks [IQR 32.0 – 64.1]). Two infants had negative birth and 6-10 week HIV-PCR results, 
four had negative 6-10 week results (no birth test) and the remaining infant was testing for 
the first time after 14 weeks old. 
Predictors of 6-10 week testing 
Maternal characteristics associated with risk of transmission were also associated with not 
receiving a 6-10 week HIV-PCR in both univariable and multivariable analyses. Infants who 
received EID at birth were 82% less likely to receive follow-up HIV-PCR than those who did 
not, after adjusting for policy period, low birth weight and prematurity, and maternal 
characteristics associated with not undergoing a 6-10 week HIV-PCR (aOR 0.18 [95% CI 0.12 
– 0.26])(Table 5). 
  6-10 week PCR done ever 
 Crude OR (95% CI) aOR (95% CI) 
Maternal age > 35y 1.47 (0.99 – 2.16) 1.32 (0.84 – 2.10) 
HIV diagnosis during pregnancy 0.71 (0.41 – 1.21) 1.10 (0.56 – 2.15) 
antenatal care - none 0.24 (0.15 – 0. 39) 0.25 (0.15 – 0.42) 
seroconversion during 
pregnancy 
0.24 (0.11 – 0.52) 0.33 (0.13 – 0.88) 
duration of art ART<12w 0.45 (0.33 – 0.61) 0.61 (0.42 – 0.88) 
viral load>1000copies/ml 0.51 (0.34 – 0.76) 0.68 (0.43 – 1.10) 
gestational  age  <37 weeks 0.56 (0.33 – 0.95) 1.12 (0.59 – 2.11) 
birth weight<2500g 0.48 (0.33 – 0.69) 0.91 (0.56 – 1.47) 
EID period 2 (versus period 1) 
EID period 3 (versus period 1) 
0.63 (0.37 – 1.10) 
0.31 (0.18 – 0.55) 
0.92 (0.48 – 1.75) 
0.61 (0.30 – 1.47) 
Birth HIV-PCR present 0.15 (0.11 – 0.20) 0.18 (0.12 – 0.26) 
Table C.5. Univariate and Multivariate analysis of predictors of having a follow-up HIV-PCR 
as per guidelines (i.e. 4-14 weeks old) ART – antiretroviral therapy; EID – early infant 
diagnosis 
6. Discussion  
To our knowledge this is the first prospective study demonstrating the real-world 
implementation of the progressive introduction of birth HIV-PCR to an EID programme in a 
routine setting.  The majority of infants received at least one HIV-PCR, most around six 
weeks old. As the indications for birth HIV-PCR expanded, the proportion receiving birth EID 
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and more than one test increased and the median age at testing decreased, but there was 
no change in the proportion of infants receiving at least one HIV-PCR. In addition, receipt of 
birth HIV-PCR significantly reduced follow-up testing. While coverage of birth HIV-PCR 
during period 3 was high overall (67%), it was considerably lower at the primary care facility 
(~35%) where >40% of deliveries occurred in this cohort. This suggests that even in a 
relatively well-resourced setting like the Western Cape, implementation of birth EID 
guidelines is challenging in primary care, the setting where most facility-based deliveries are 
likely to occur in sub-Saharan Africa.  
Data presented in a review of the first year of the SA national programme demonstrated an 
increase in birth EID coverage from 39% (high-risk) to 93% within 12 months of the national 
guideline change with  a corresponding drop in six-weeks testing (to 19%); the increase in 
10-week tests was modest (13). In our study, the majority of all birth testing occurred in 
infants born in hospital. During the first two policy periods, this could be expected owing to 
the definition of some high-risk criteria (prematurity, low birth weight). This is reflected in 
an analysis of Western Cape laboratory data in which, while the numbers of facilities 
offering birth EID increased during period 2, the majority of tests continued to be performed 
in hospitals: 67% versus 33% sent from primary care (14). The national programme data (13) 
were not stratified by level of care and there are still limited data on how the EID 
recommendations are implemented in primary care facilities and in rural areas across SA.  
Risk Factors for Vertical Transmission 
Almost half of all infants presented with at least one high-risk factor for vertical 
transmission, yet only 30.8% received birth HIV-PCR during period 2, the majority of those 
being premature and low birth weight infants (i.e. likely to be born in hospital). Although the 
likelihood of receiving a birth test increased with increasing number of risk factors, many 
infants at high risk were missed.  
Nevertheless, these data demonstrate the maturation of the HIV treatment programme in 
Cape Town and some progress towards addressing vertical transmission risk factors: over 28 
months an increasing number of women entered antenatal care known to be HIV-infected, 
had conceived on ART and were on ART for longer durations before delivery.  
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HIV Transmission and Follow-up Testing 
The number of HIV-infected infants in the cohort was low so data need to be interpreted 
with caution. Overall vertical HIV transmission was 1.6%. This compares with a national rate 
of 1.4% at six-weeks in 2016 down from 2.4% in 2012 (15, 16). In utero transmission was 
1.7% on average, highest during periods 1 (3.6%) and 2 (2.3%) when a sample of high-risk 
infants was selected. A hospital-based retrospective cohort study in Cape Town found a 
similar in utero transmission rate of 3.8% under a programme of targeted birth EID (17). 
When the sample of exposed infants tested at birth is expanded to include those at low risk 
of infection, a reduced transmission rate would be expected. The average in utero 
transmission rate during the first year of the national birth EID programme was 1.1%; when 
stratified by province it was 2.6% in the Western Cape but the interval overlapped both 
period 2 and period 3 suggesting that the sample may have been biased towards high-risk 
infants and is closer to that in period 2 (13). The discrepancy may also be due to the 
maternal HIV prevalence in our study sample (14.7% at delivery) versus 18.9% for the whole 
province (18). In a Johannesburg hospital sample in utero transmission rate was 1.4% during 
period 3 (19). 
The detection rate between birth and 6-10 weeks was lower than at birth except in period 3; 
this compares with rates of 0.4 – 0.5% in a hospital cohort during the same period of 
targeted birth testing (17). During period 3 there were no positive birth HIV-PCR results and 
the detection rate from birth to 6-10 weeks was 2.4% (versus national rates of 1.4% at six 
weeks (13).) Almost half of these infants had a negative birth test indicating late intra-
partum or early post-natal transmission and reinforcing the necessity of follow-up testing. 
Our study provides additional evidence that receipt of birth HIV-PCR decreased the 
presentation for follow-up testing (13, 14, 17). Receipt of birth EID reduced the likelihood of 
subsequent HIV testing after six-weeks by 82%, even when controlling for other risk factors. 
This concurs with a retrospective analysis of a Cape Town hospital sample in which infants 
who had birth HIV-PCR were 40% less likely to present for follow-up testing (17); when 
follow-up did occur in the birth cohort it was at older ages than among those who did not 
have birth EID (8.6 versus 7.1 weeks). We found that age of subsequent HIV-PCR was 
greatest during the period of maximum birth testing, i.e. 8.6 weeks in period 3; appropriate 
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as the time-point for testing had shifted from six to 10 weeks. In a sensitivity analysis to 
assess the influence of birth EID on the likelihood of ever having a repeat HIV-PCR after four 
weeks old (i.e. not restricted to the 6-10 week window), the direction of the associations 
remained unchanged. These findings are concerning given that the modelling data that 
supported the introduction of birth EID in SA demonstrated a loss of effectiveness if return 
for follow-up testing dropped below 63% (5).  In addition, at least 11 HIV infected infants in 
this cohort (35.5%) were late intra-partum or postnatally infected, emphasising the need for 
testing after the birth time-point. In contrast to the SA data, interim analysis of women in 
Lesotho indicated that the majority of women who received very early EID (within two 
weeks of birth) returned for results and follow-up testing at six-weeks(20, 21).  
The proportion of indeterminate results was low at all time-points, but accounted for 15.4% 
and 55.6% of non-negative results at birth and 6-10 weeks respectively. Similar results were 
reported in a review of birth EID in Johannesburg, 0.4% of all results, 24% of non-negative 
results were indeterminate (22). In the Johannesburg study, additional resources were 
required to trace and retest these neonates. In our cohort all the infants were negative on 
repeat testing, which is in contrast to both the Johannesburg study and to a laboratory-
based cohort which demonstrated increased likelihood that infants with indeterminate HIV-
PCR result would be positive on subsequent testing in a setting of intensified VTP regimens 
(22, 23). It is possible that the repeat negative HIV-PCR results in our report were false 
negatives in the face of prolonged infant post-exposure prophylaxis and exposure to ART in 
breast-milk. 
Strengths and limitations 
We present prospective individual longitudinal follow-up on a cohort of HIV-exposed infants 
born at a primary care facility as well as in hospital. The cohort has an advantage over the 
aggregate laboratory data (13, 14) in that HIV-PCR results could be attributed to individual 
linked mother-infant pairs. One of the acknowledged challenges of using routine laboratory 
data for surveillance in SA is the lack of an unique patient identifier and the inability to 
accurately de-duplicate data (13, 15).  Although the Western Cape has made substantial 
progress with issuing unique identifiers to infants at birth, operational challenges remain, 
and our sample was limited to linked mother-infant pairs, compromising numbers that could 
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be included, especially in period 1. While our study is strengthened by demonstrating real-
world implementation of expanded EID guidelines, it is consequently also dependent on the 
quality of routine clinical sources and we were unable to account for missing data. It is 
possible that not all the relevant HIV-PCRs were recorded as an infant could have numerous 
alternative identifiers; we were also unable to determine whether HIV-PCR tests occurred 
outside the Western Cape. Some infants died before follow-up testing. Prematurity and low 
birth weight contribute to infant mortality independent of HIV infection. Similarly infants 
may have been too acutely unwell to undergo birth EID. 
7. Conclusions 
In this study we assessed the impact of different birth EID strategies, that of targeted birth 
testing of high-risk infants, and universal testing of all HIV-exposed infants. Targeted birth 
EID identified more HIV-infected infants early, some of whom may otherwise have died 
before six-weeks. However, universal testing simplified the VTP guidelines and increased the 
proportion of infants tested at birth. While our data demonstrate an encouraging response 
to EID guideline changes, birth HIV-PCR was not well implemented at primary care level.  
Birth EID also compromises follow-up testing at six or 10 weeks and this LTFU may negate 
the model-predicted benefits of birth HIV-PCR (5). Additional intervention is required to 
reduce risk factors for transmission, to expand birth EID at primary care and to improve 
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Appendix 1: Closing the Gaps
Towards pediatric HIV elimination: Closing the gaps in prevention of mother-to-child transmission 
(PMTCT) programme coverage, early infant diagnosis and treatment.  
(Short title: “Closing the Gaps”) 
1. Background and project outline 
Virtual elimination of vertical transmission of HIV is within reach in South Africa. Despite high antenatal 
HIV prevalence, implementation of currently available technology and guidelines in the South African 
Prevention of Mother-to-Child Transmission (PMTCT) programme has resulted in substantial reductions 
in vertically transmitted HIV to 3.5% across the country, and <2% in the Western Cape (WC). Yet, 
elimination remains elusive due to persistent coverage gaps and “drop-offs” at each of the steps 
required in completion of the PMTCT and infant care continuum, with upwards of 1000 vertically 
infected infants born in the Western Cape each year. We hypothesize that these persistent coverage 
gaps are the most important remaining barrier to near-elimination of pediatric HIV morbidity and 
mortality, irrespective of intensification of PMTCT regimens. 
There is thus a need for research to identify strategies that provide an early warning system of coverage 
gaps both at the level of the health system and the individual, and link to care pregnant women and HIV-
exposed/infected infants with such gaps who critically need antiretroviral therapy (ART) or interventions 
to prevent transmission.  
2. Purpose and objectives: 
The purpose of this study is to implement and evaluate three linked active surveillance activities 
integrated with the existing service platform that aim to iteratively identify and close PMTCT, early 
infant diagnosis and ART coverage gaps. The study will be carried out by the Centre for Infectious 
Disease Epidemiology and Research (CIDER) from the UCT School of Public Health and Family Medicine 
in partnership with the WC Department of Health (DoH). The study will be conducted at the Gugulethu 
Midwife Obstetric Unit (GMOU) in the Klipfontein sub-district, and its referral facilities, Mowbray 
Maternity Hospital (MMH) and Groote Schuur Hospital (GSH).  
The three activities are as follows: 
1. Routine cord blood surveillance (CBS) for HIV exposure and, if positive, the presence of antiretroviral 
drugs (ARVs): This will be linked to the existing programme of screening for congenital hypothyroidism. 
CBS will enable identification and urgent linking to care of HIV-exposed infants with no/suboptimal 
peripartum ARVs to ensure interventions to prevent postnatal transmission, prompt infant diagnosis and 
infant ART if infected.  
2. A single integrated electronic PMTCT register (e-register) linking existing separate paper-based 
registers held at antenatal, obstetric and infant clinics in the Klipfontein subsdistrict, as well as NHLS 
laboratory data (maternal CD4, infant PCR). Unlike existing registers that report on aggregate coverage 
of individual steps in the PMTCT pathway, the combined e-register will track an individual pregnant 
woman’s trajectory through PMTCT and identify where drop-offs and missed opportunities occur. The e-
register will therefore support systems of urgent reporting of laboratory results of low CD4 counts in 
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pregnant women and positive infant HIV-PCR test results to clinics, with tracing to ensure prompt ART 
initiation. 
3. Clinical quality assurance and improvement using CBS and PMTCT e-register data.  This will be 
developed in partnership with DoH service managers and integrated with existing subdistrict 
programme review processes.  
These activities thus aim to close coverage gaps at 2 levels: 
At an individual level: For individual mothers and infants interventions are designed to ensure 
appropriate linkages to care will be triggered at key points in the PMTCT cascade.  
At a health system level: An auditable early warning system of coverage gaps across the entire program, 
and interrogation of the reasons for ongoing vertical transmission, will inform and be integrated into 
clinical quality assurance systems. 
 
Objectives of the study are therefore as follows:  
1. To compare PMTCT programme outcomes and effectiveness before and after implementation of 
these surveillance activities. Measures of programme outcomes and effectiveness to be compared will 
include:  
Vertical transmission proportion  
Proportion of women presenting at delivery without a previous HIV test  
Proportion of women with incident HIV infection during pregnancy  
Proportion of mother-infant pairs “dropping off” at each step of the cascade (e-register and CBS). 
 
2. To assess the feasibility and success of implementation of the project by measuring, for example, CBS 
coverage, completeness and quality of PMTCT e-register data entry and linkage, proportion of those 
identified by the e-register and/or CBS as needing additional intervention who are successfully traced 
and linked to appropriate care, compliance with clinical quality assurance review meetings.   
All data needed for the above objectives will be collected through implementation of CBS and the e-
register. 
3. Implementation and recruitment 
Briefly we aim to implement the 3 activities as follows: 
 
3.1. Cord blood surveillance 
The project will build on the existing system of congenital hypothyroidism screening, using routine 
systems for collection of a specimen of cord blood, specimen transport, registration and testing.  A 
research assistant will visit GMOU, MMH and GSH twice a week to support and monitor the collection of 
cord-blood specimens. Recruitment of p  take place at the antenatal 
booking visit at GMOU. As part of counselling and testing for routine opt-out antenatal HIV testing that 
is standard of care, a study counsellor will work with existing counselling staff to obtain informed 
consent (IC) to participate in the study. This will include consent for a rapid HIV test to be performed on 
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a cord blood specimen taken at delivery and, if HIV positive, 2 dried blood spot specimens to be tested 
for the presence of ARVs. HIV tests will be performed at the NHLS laboratory at Red Cross Children’s 
Hopsital and tests for ARVs at the UCT Department of Pharmacology. The process of obtaining IC will 
include explaining the risks and benefits of participation (including that testing may lead to more active 
tracing and follow-up of the patient if results indicate that there is a high risk of transmission), the 
alternatives to participation, and that the decision to participate will in no way affect the medical care 
provided. Patients consenting to participate in the study will be provided with an information sheet and 
informed that they may withdraw from the study at any time. In particular, at delivery, women will be 
reminded that they have given consent for cord blood testing, and given the opportunity to withdraw 
from the study. For women who arrive at GMOU in labour without a previous antenatal booking, we will 
attempt to obtain consent during labour to participate in the study. This will be done to ensure that 
coverage of CBS is as complete as possible, and that “unbooked” women are also able to access the 
benefits of study participation. All consent procedures, information sheets and reminders of study 
involvement will be performed/translated into all local languages. 
Infants at high risk of HIV infection (cord blood HIV positive, no/sub-optimal ARVs) will be traced and 
linked to care by a study community outreach worker working with existing health service PMTCT 
support staff. This will include counseling regarding the HIV diagnosis to the mother if this was 
previously unknown. Mother-infant pairs will be linked to routine PMTCT/MCH services so that 
interventions to reduce the risk of postnatal transmission as well as early infant PCR testing (with early 
ART if positive) can be provided. Data from HIV-exposed infants with ARVs present in cord blood will be 
linked to laboratory data to determine whether PCR testing occurs timeously. The same tracing staff will 
seek infants not tested by  of age and link them to care.  
2. Electronic PMTCT Register  
PMTCT data from women delivering at GMOU as well as women referred from GMOU to MMH and GSH, 
will be linked with data from the antenatal and infant follow-up clinics associated with GMOU, as well as 
with laboratory data to establish a single PMTCT e-register. Linkage fields will include the WC unique 
patient health numbers, maternal and infant names, birth dates, delivery dates and infant birth dates. A 
very high proportion of true matches are readily linkable when the linkage sets are restricted by location 
(facility) or date (e.g. birth date of infant and delivery date of mother). The proportion of records that 
cannot be linked will indicate the disjunction in each step in the PMTCT continuum, providing early 
warning of coverage gaps.  
The e-register will support urgent notification of clinics of laboratory results of maternal CD4 <350 
positive infant PCR tests. These will be identified through daily updates of laboratory results 
from the NHLS to the research officer at CIDER for incorporation into the e-register. The research officer 
will work with existing reporting systems to inform the relevant clinic/health service staff of any positive 
test results. We will work with existing WC and City of Cape Town HIV/AIDS and PMTCT to ensure 
tracing and treatment initiation for these HIV-infected women and infants needing ART.  
There will be no recruitment and we are requesting a waiver of informed consent for this part of the 
project. We will only be incorporating data already collected as part of routine care by the health 
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services and for which informed consent was given when women consented to standard of care routine 
antenatal opt-out HIV testing. 
3. Clinical quality assurance and improvement 
Monthly program reviews will be implemented in partnership with Department of Health service 
managers and be informed by data arising from the PMTCT e-register and CBS. For example: 
Sentinel events of new cases of infant HIV identified through the e-register will be reviewed to 
identify reasons for transmission. 
Coverage gaps at each step of the PMTCT cascade in women on the PMTCT program as identified 
through the e-register will be reviewed. 
Coverage gaps in all steps of the cascade up to and including delivery as measured by CBS data will 
be reviewed. 
No maternal or infant identifiers will be used or mentioned at all in these reviews. 
4. Description of risks and benefits: 
4.1. Potential risks to subjects and their likelihood and seriousness 
The major risk for all 3 components will be breach of confidentiality - project staff will have access to 
individually identifiable maternal and infant HIV and ARV cord blood results, and trace high risk 
transmission mother-infant pairs. A small number of women will be recruited for CBS in labour and this 
may pose a psychological risk. Patient autonomy may also be compromised and privacy breached, as the 
circumstances in labour may not provide adequate opportunity for counseling and informed consent 
according to service protocol. This could be considered morally controversial. However, it is argued that 
withholding the right to consent to HIV testing and treatment to a woman of unknown serostatus 
compromises her autonomy to have the choice of her infant receiving interventions to prevent vertical 
transmission if she is HIV infected, even if consent needs to be sought during labour. The study offers 
clear benefits to mother-infant pairs identified as HIV infected for the first-time at delivery (opportunity 
to receive proven effective interventions to prevent post-natal transmission, active follow-up and 
linkage to HIV/ART care) so it would be unethical to exclude women presenting for the first time when 
already in labour. This is the group for whom the benefits of participation may be the greatest. Rapid 
HIV testing in labour is recommended in other service settings e.g. “opt out” testing in labour for a 
woman of unknown serostatus is standard of care in the United States. 
 
4.2. Adequacy of Protection Against Risks  
The process of obtaining informed consent for CBS in such a way as to minimize risks, ensure that 
women fully understand the risks of participation and have autonomy to refuse participation or 
withdraw from the study have been described above. In particular, we will only use qualified HIV 
Counseling and Testing (HCT) counselors and will employ additional counselors to support DoH 
counselors to ensure adequate quality of the informed consent process. For women recruited during 
labour we will ensure that counseling is conducted in privacy and that the benefits and risks of cord 
blood HIV testing are fully explained. Since a pregnant woman in labour is particularly vulnerable, we 
will be sure that women clearly understand that the quality of health care they receive will not be 
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compromised should they elect not to participate. Should a woman with no prior antenatal care present 
too late in labour for there to be time for her to be invited to participate in the study, the midwife will 
collect the additional cord blood specimen, and after delivery is complete, the woman will be invited to 
participate in the study and have the specimen tested for HIV/ARVs. Specimens from women who 
decline to participate post-delivery will be discarded. 
 
Tracing and linkage to care of pregnant women eligible for ART and infants identified as HIV-infected or 
at high risk of vertical transmission will be done carefully and sensitively. Pregnant women/mothers of 
infants will be telephoned and asked to attend the clinic urgently for a health care appointment. Where 
telephonic tracing is unsuccessful, a home visit will be done and the patient asked to attend the clinic for 
a health care appointment. No laboratory results will be given to the mother telephonically or at the 
home visit. Results will only be given to the mother at the clinic appointment in a private room by 
qualified health service providers as per South African PMTCT and HCT guidelines ensuring patient 
confidentiality. Full post-test counselling will be given to the mother according to HCT guidelines. 
 
All HIV counselling and testing (antenatally and during labour or post-delivery) will be offered by 
qualified health service providers as per HCT and PMTCT guidelines ensuring patient confidentiality and 
autonomy.  
 
To minimize risks of breaching confidentiality, all electronic project data will be stored in a password-
protected database on a secure server housed in the CIDER offices at the UCT Faculty of Health Sciences, 
with user level access control implemented. Any paper based patient records will be stored in locked 
filing cabinets in locked room with access only to those directly involved in the study. Inclusion of 
identifiers in the databases is needed initially so that they can be linked and for tracing of 
mothers/infants. Identifiers will be removed from all databases (PMTCT e-register and CBS HIV and ARV 
results) as soon as possible once linkage and tracing are complete. Only staff directly involved in the 
project will have access to the data and will undergo Human Subjects Protection training prior to having 
access to any individually identifiable data. We will use the same measures to protect against breach of 
confidentiality as are currently in place in all CIDER projects. Thus far, no breach of confidentiality has 
occurred in any of these projects. Should a breach of confidentiality occur in this project, it will be noted 
and investigated. 
 
4.3 Potential benefits 
Historically, antenatal sentinel surveillance and monitoring of PMTCT programmes has been based on 
anonymous specimens and aggregate data. While these provide surveillance for the programme as a 
whole, they provide no opportunity to act on clinically important results, and thus fail to benefit the 
individual patient on whom testing has been performed.  
 
This study thus has the following benefits: 
• It will generate surveillance data and early warning systems that will trigger and inform PMTCT 
programme improvement, thus benefiting all HIV-infected mother-infants pairs in the area where the 
study takes place.  
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• It provides individual benefit to mothers and infants participating in the study by identifying pregnant 
women eligible for ART, HIV-infected infants and those at high risk of transmission and prioritizing 
provision of immediate PMTCT and maternal and infant HIV care interventions that are known to be 
access to these benefits. 
• The surveillance systems will be developed in partnership with health services with a long term view 
to more widespread routine adoption, so that HIV-infected women and exposed infants from other 
areas will also benefit if the project is successfully expanded to other areas and integrated into 
routine surveillance. 
• The findings of the study will inform PMTCT programmes broadly in terms of improving coverage and 
maximizing the benefits of ART for maternal and child health. 
 
4.4. Balancing the major risks to subjects with the potential benefits of the project 
Breach of confidentiality:  As every effort will be taken to ensure confidentiality, the small risk of it 
being breached can be considered to be acceptable given the potential not only to achieve PMTCT 
programmatic improvements, but also to provide individual benefit to study participants through tracing 
and linkage to care. Of note, the individual benefits could not be provided without the holding of 
identified laboratory test results, so this is an unavoidable risk. 
Compromise of patient autonomy and psychological distress for women recruited during labour:  
While optimal strategies for PMTCT comprise early antenatal diagnosis and treatment, testing pregnant 
women of either unknown serostatus or with acute infection at the time of delivery provides an 
additional opportunity for PMTCT. Given the availability of effective maternal and infant ART the 
potential immediate benefit to mother and child of a pregnant woman learning her serostatus 
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Figure 1: Algorithm: Prevention of Mother-to-Child Transmission 
PMTCT Clinical Guidelines Update June 2014
Appendix 2: Western Cape Vertical Transmission Prevention of HIV
and Early Infant Diagnosis Algorithms
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The Introduction section should introduce the topic to readers without specialist knowledge in 
that area and must clearly outline the current state of knowledge in this field, the motivation and 
the aim of the study or the article.
Methods
The Methods section should include all information necessary to repeat the study, in particular, 
the study design, how data was collected and analyzed, clarifying the choice of methods that 
were made. If applicable, you should describe the setting of the study, the dates the study were 
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materials, including statistical packages, used. Interventions and programmes should be 
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Results
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should not contain identifiable information to ensure confidentiality. Clarifications within the 
quotation should be placed in square brackets.
Submitting authors are strongly encouraged to include data disaggregated by sex (and, 
whenever possible, by race) and provide a comprehensive analysis of gender and racial 
differences. The authors should include the number and percentage of men, women and, if 
appropriate, transgender persons who participated in the research study. Anatomical and 
physiological differences between men and women (height, weight, body fat-to-muscle ratios, cell 
counts, hormonal cycles, etc.), as well as social and cultural variables (socio-economic, 
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context of the current body of knowledge in the field. Limitations of the study, for example, 
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